Appendix B: 2008 Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS) annual report – Minimal inhibitory concentration tables

Appendix B - Minimal Inhibitory Concentration Tables

The following information is important for the interpretation of tables presenting results on the distribution of minimal inhibitory concentrations (MICs).

• Roman numerals I to IV indicate the ranking of human medicine importance as outlined by the Veterinary Drugs Directorate, Health Canada.
• The unshaded fields indicate the range tested for each antimicrobial in the plate configuration.
• Red numbers indicate the percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.
• Numbers to the right of the highest concentration in the tested range (i.e. red numbers in shaded fields) represent the percentage of isolates with growth in all wells within the tested range, indicating that the actual MICs were greater than the tested range of concentrations.
• Numbers at the lowest concentration in the tested range (i.e. blue numbers at the far left in unshaded fields) represent the percentage of isolates susceptible to the antimicrobial at the indicated or lower concentrations.
• Solid vertical lines represent resistance breakpoints.
• Dotted vertical lines represent susceptibility breakpoints.
• MIC 50 = MIC at which 50% of isolates were inhibited by a specific antimicrobial.
• MIC 90 = MIC at which 90% of isolates were inhibited by a specific antimicrobial.
• %R = Percentage of isolates that were resistant to a specific antimicrobial.

Humans

Table B.1. Distribution of minimal inhibitory concentrations for antimicrobials in Salmonella Enteritidis isolates from humans; Surveillance of Human Clinical Isolates, 2008.

Information on how to interpret the MIC tables is provided at the beginning of Appendix B.

Table B.1. - Text Equivalent

Antimicrobial		n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
			MIC 50	MIC 90		≤ 0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	> 256
I	Amoxicillin-clavulanic acid	1,258	≤ 1	≤ 1	0.2							94.5	2.9	0.3	1.9	0.1	0.2	0.1
	Ceftiofur	1,258	1	1	0.2				0.2	0.2	3.3	94.8	1.5			0.2
	Ceftriaxone	1,258	≤ 0.25	≤ 0.25	0.2					99.7	0.2					0.2
	Ciprofloxacin	1,258	≤ 0.015	0.12	0.0	82.4	3.7	0.3	7.4	4.7	1.5
II	Amikacin	1,258	1	2	0.0						12.8	75.4	11.3	0.5
	Ampicillin	1,258	≤ 1	≤ 1	2.6							90.5	6.4	0.6				2.6
	Cefoxitin	1,258	2	2	0.2							3.6	89.2	6.2	0.8		0.2	0.1
	Gentamicin	1,258	≤ 0.25	0.50	0.2					68.5	30.0	1.2				0.2	0.1
	Kanamycin	1,258	≤ 8	≤ 8	0.2										99.8				0.2
	Nalidixic acid	1,258	4	> 32	12.6								24.2	61.1	1.0	1.1	0.2	12.3
	Streptomycin	1,258	≤ 32	≤ 32	0.9												99.1	0.2	0.7
	Trimethoprim-sulfamethoxazole	1,258	≤ 0.12	0.25	0.4				86.2	12.8	0.6			0.1	0.3
III	Chloramphenicol	1,258	4	8	0.1								0.6	59.5	39.5	0.3		0.1
	Sulfisoxazole	1,258	32	64	1.0											3.0	64.0	31.4	0.5	0.2	1.0
	Tetracycline	1,258	≤ 4	≤ 4	1.6									98.4		0.1	0.1	1.4
IV

Table B.2. Distribution of minimal inhibitory concentrations for antimicrobials in Salmonella Heidelberg isolates from humans; Surveillance of Human Clinical Isolates, 2008.

Information on how to interpret the MIC tables is provided at the beginning of Appendix B.

Table B.2. - Text Equivalent

Antimicrobial		n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
			MIC 50	MIC 90		≤ 0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	> 256
I	Amoxicillin-clavulanic acid	290	≤ 1	32	13.4							66.6	1.7	0.3	4.1	13.8	7.9	5.5
	Ceftiofur	290	1	> 8	14.1				0.3		23.4	61.7	0.3		0.3	13.8
	Ceftriaxone	290	≤ 0.25	16	14.1					85.9				0.3	0.3	11.4	1.7	0.3
	Ciprofloxacin	290	≤ 0.015	≤ 0.015	0.0	99.7	0.3
II	Amikacin	290	1	2	0.0						1.0	53.8	40.7	4.5
	Ampicillin	290	≤ 1	> 32	31.7							67.2	1.0					31.7
	Cefoxitin	290	2	32	13.1							31.7	49.0	5.2	0.7	0.3	4.5	8.6
	Gentamicin	290	0.50	0.50	2.4					27.6	63.4	6.2	0.3			0.3	2.1
	Kanamycin	290	≤ 8	≤ 8	1.0										98.6	0.3			1.0
	Nalidixic acid	290	2	4	0.0								62.1	37.6	0.3
	Streptomycin	290	≤ 32	≤ 32	6.9												93.1	4.1	2.8
	Trimethoprim-sulfamethoxazole	290	≤ 0.12	0.25	1.4				77.6	20.7			0.3	0.3	1.0
III	Chloramphenicol	290	8	8	0.7									16.9	81.7	0.7		0.7
	Sulfisoxazole	290	32	64	3.8											22.1	67.6	6.6			3.8
	Tetracycline	290	≤ 4	≤ 4	6.2									93.8				6.2
IV

Table B.3. Distribution of minimal inhibitory concentrations for antimicrobials in Salmonella Newport isolates from humans; Surveillance of Human Clinical Isolates, 2008.

Information on how to interpret the MIC tables is provided at the beginning of Appendix B.

Table B.3. - Text Equivalent

Antimicrobial		Percentiles			% R	Distribution (%) of MICs (µg/mL)
		n	MIC 50	MIC 90		≤ 0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	> 256
I	Amoxicillin-clavulanic acid	177	≤ 1	≤ 1	1.1							96.6	0.6		1.7			1.1
	Ceftiofur	177	1	1	1.7				0.6		27.7	70.1				1.7
	Ceftriaxone	177	≤ 0.25	≤ 0.25	1.7					98.3							0.6	0.6	0.6
	Ciprofloxacin	177	≤ 0.015	≤ 0.015	0.0	98.9			0.6	0.6
II	Amikacin	177	1	2	0.0						0.6	60.5	37.9	1.1
	Ampicillin	177	≤ 1	≤ 1	2.8							95.5	1.7					2.8
	Cefoxitin	177	2	2	1.1						0.6	10.7	81.4	5.6	0.6			1.1
	Gentamicin	177	0.50	0.50	0.6					27.7	69.5	1.1	1.1				0.6
	Kanamycin	177	≤ 8	≤ 8	0.6										99.4				0.6
	Nalidixic acid	177	2	4	1.1							1.1	71.8	26.0				1.1
	Streptomycin	177	≤ 32	≤ 32	2.3												97.7	0.6	1.7
	Trimethoprim-sulfamethoxazole	177	≤ 0.12	0.25	1.1				85.9	13.0					1.1
III	Chloramphenicol	177	4	8	1.7								1.7	82.5	14.1			1.7
	Sulfisoxazole	177	64	64	2.8											2.8	38.4	52.0	3.4	0.6	2.8
	Tetracycline	177	≤ 4	≤ 4	4.0									96.0		0.6		3.4
IV

Table B.4. Distribution of minimal inhibitory concentrations for antimicrobials in Salmonella Paratyphi A and S. Paratyphi B isolates from humans; Surveillance of Human Clinical Isolates, 2008.

Information on how to interpret the MIC tables is provided at the beginning of Appendix B.

Table B.4. - Text Equivalent

Antimicrobial		n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
			MIC 50	MIC 90		≤ 0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	> 256
I	Amoxicillin-clavulanic acid	65	≤ 1	2	3.1							55.4	40.0			1.5	3.1
	Ceftiofur	65	1	1	1.5						6.2	90.8	1.5			1.5
	Ceftriaxone	65	≤ 0.25	≤ 0.25	1.5					98.5						1.5
	Ciprofloxacin	65	0.50	0.50	0.0	26.2	1.5				70.8	1.5
II	Amikacin	65	0.50	1	0.0						75.4	15.4	9.2
	Ampicillin	65	2	2	4.6							16.9	76.9		1.5			4.6
	Cefoxitin	65	4	8	1.5							4.6	12.3	69.2	12.3			1.5
	Gentamicin	65	≤ 0.25	0.50	1.5					83.1	12.3	3.1					1.5
	Kanamycin	65	≤ 8	≤ 8	1.5										98.5				1.5
	Nalidixic acid	65	> 32	> 32	72.3								10.8	16.9				72.3
	Streptomycin	65	≤ 32	≤ 32	4.6												95.4		4.6
	Trimethoprim-sulfamethoxazole	65	≤ 0.12	0.25	1.5				58.5	40.0					1.5
III	Chloramphenicol	65	8	8	4.6									9.2	84.6	1.5		4.6
	Sulfisoxazole	65	32	64	4.6											7.7	75.4	12.3			4.6
	Tetracycline	65	≤ 4	≤ 4	6.2									93.8			1.5	4.6
IV

Table B.5. Distribution of minimal inhibitory concentrations for antimicrobials in Salmonella Typhi isolates from humans; Surveillance of Human Clinical Isolates, 2008.

Information on how to interpret the MIC tables is provided at the beginning of Appendix B.

Table B.5. - Text Equivalent

Antimicrobial		n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
			MIC 50	MIC 90		≤ 0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	> 256
I	Amoxicillin-clavulanic acid	186	≤ 1	8	0.0							82.8	0.5	1.1	11.3	4.3
	Ceftiofur	186	0.50	1	0.0				1.1	2.2	75.3	21.5
	Ceftriaxone	186	≤ 0.25	≤ 0.25	0.0					100.0
	Ciprofloxacin	186	0.25	0.25	0.0	16.1		11.8	14.5	51.1	5.9		0.5
II	Amikacin	186	1	1	0.0						10.2	85.5	4.3
	Ampicillin	186	≤ 1	> 32	16.7							82.8	0.5					16.7
	Cefoxitin	186	4	8	0.0						1.1	20.4	13.4	53.2	11.8
	Gentamicin	186	≤ 0.25	0.50	0.0					82.3	17.2	0.5
	Kanamycin	186	≤ 8	≤ 8	0.5										99.5				0.5
	Nalidixic acid	186	> 32	> 32	69.4							1.1	13.4	14.5	1.6			69.4
	Streptomycin	186	≤ 32	> 64	17.7												82.3	1.1	16.7
	Trimethoprim-sulfamethoxazole	186	≤ 0.12	> 4	17.2				72.6	10.2					17.2
III	Chloramphenicol	186	4	> 32	17.7								1.6	67.2	13.4			17.7
	Sulfisoxazole	186	32	> 256	18.3											28.0	45.7	7.5	0.5		18.3
	Tetracycline	186	≤ 4	≤ 4	5.9									94.1				5.9
IV

Table B.6. Distribution of minimal inhibitory concentrations for antimicrobials in Salmonella Typhimurium isolates from humans; Surveillance of Human Clinical Isolates, 2008.

Information on how to interpret the MIC tables is provided at the beginning of Appendix B.

Table B.6. - Text Equivalent

Antimicrobial		n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
			MIC 50	MIC 90		≤ 0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	> 256
I	Amoxicillin-clavulanic acid	474	≤ 1	16	2.5							68.4	0.8	1.5	11.2	15.6	0.8	1.7
	Ceftiofur	474	1	1	2.3						10.3	85.7	1.7			2.3
	Ceftriaxone	474	≤ 0.25	≤ 0.25	2.3					97.5	0.2					0.8	0.6	0.6	0.2
	Ciprofloxacin	474	≤ 0.015	≤ 0.015	0.0	94.7	2.1		0.4	1.7	0.8	0.2
II	Amikacin	474	2	2	0.0							46.4	51.1	2.5
	Ampicillin	474	≤ 1	> 32	30.6							67.1	1.9	0.4			0.4	30.2
	Cefoxitin	474	2	4	2.3							8.4	78.3	9.3	1.7		0.2	2.1
	Gentamicin	474	0.50	1	2.5					13.3	74.9	9.3				0.2	2.3
	Kanamycin	474	≤ 8	> 64	12.4										87.3	0.2		0.2	12.2
	Nalidixic acid	474	2	4	2.1								61.4	34.8	1.5	0.2		2.1
	Streptomycin	474	≤ 32	> 64	30.4												69.6	15.0	15.4
	Trimethoprim-sulfamethoxazole	474	≤ 0.12	0.25	5.1				56.1	36.5	2.3			0.2	4.9
III	Chloramphenicol	474	8	> 32	21.1								0.6	33.8	44.1	0.4		21.1
	Sulfisoxazole	474	32	> 256	32.9											3.0	52.3	11.6	0.2		32.9
	Tetracycline	474	≤ 4	> 32	32.1									67.9		8.0	9.7	14.3
IV

Table B.7. Distribution of minimal inhibitory concentrations for antimicrobials in Salmonella "Other Serovars" isolates from humans; Surveillance of Human Clinical Isolates, 2008.

Information on how to interpret the MIC tables is provided at the beginning of Appendix B.

Table B.7. - Text Equivalent

Antimicrobial		n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
			MIC 50	MIC 90		≤ 0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	> 256
I	Amoxicillin-clavulanic acid	1,151	≤ 1	≤ 1	1.7							91.4	1.7	1.0	2.1	2.3	0.4	1.2
	Ceftiofur	1,151	1	1	1.8				0.1	0.3	28.7	67.2	1.7	0.2	0.2	1.7
	Ceftriaxone	1,151	≤ 0.25	≤ 0.25	1.8					98.2				0.1	0.1	1.2	0.3	0.1	0.1
	Ciprofloxacin	1,151	≤ 0.015	≤ 0.015	1.0	92.1	1.0	0.7	1.2	2.2	1.0	0.7	0.1		1.0
II	Amikacin	1,151	1	2	0.0						1.0	53.4	43.0	2.4	0.2
	Ampicillin	1,151	≤ 1	≤ 1	6.3							91.0	1.8	0.4	0.2	0.3		6.3
	Cefoxitin	1,151	2	4	2.0							10.0	57.3	28.7	1.9	0.1	0.3	1.7
	Gentamicin	1,151	0.50	0.50	2.4					22.7	68.7	5.7	0.3		0.1	0.6	1.8
	Kanamycin	1,151	≤ 8	≤ 8	1.5										97.6	0.7	0.3	0.1	1.4
	Nalidixic acid	1,151	2	4	4.9							0.4	65.5	26.7	1.8	0.7	0.1	4.8
	Streptomycin	1,151	≤ 32	64	12.8												87.2	6.4	6.3
	Trimethoprim-sulfamethoxazole	1,151	≤ 0.12	0.25	3.5				80.8	14.2	1.3		0.2		3.5
III	Chloramphenicol	1,151	8	8	3.0								0.4	45.4	50.5	0.7	0.2	2.9
	Sulfisoxazole	1,151	64	> 256	10.7											7.7	41.0	38.0	2.4	0.2	10.7
	Tetracycline	1,151	≤ 4	> 32	19.5									80.1	0.3	0.3	4.9	14.3
IV

Beef Cattle

Table B.8. Distribution of minimal inhibitory concentrations for antimicrobials in Salmonella isolates from cattle; Surveillance of Animal Clinical Isolates, 2008.

Information on how to interpret the MIC tables is provided at the beginning of Appendix B.

Table B.8. - Text Equivalent

Antimicrobial		n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
			MIC 50	MIC 90		≤ 0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	> 256
I	Amoxicillin-clavulanic acid	134	≤ 1	16	4.5							61.9	3.7	1.5	11.9	16.4	1.5	3.0
	Ceftiofur	134	1	1	4.5					0.7	30.6	59.0	5.2			4.5
	Ceftriaxone	134	≤ 0.25	≤ 0.25	4.5					95.5						3.7	0.7
	Ciprofloxacin	134	≤ 0.015	≤ 0.015	0.0	94.8	4.5			0.7
II	Amikacin	134	1	2	0.0						5.2	53.7	36.6	3.7		0.7
	Ampicillin	134	≤ 1	> 32	32.8							61.9	3.7	0.7	0.7			32.8
	Cefoxitin	134	2	4	4.5							10.4	61.2	19.4	4.5		3.7	0.7
	Gentamicin	134	0.50	1	6.0					48.5	38.1	6.7	0.7			3.7	2.2
	Kanamycin	134	≤ 8	> 64	23.9										76.1			0.7	23.1
	Nalidixic acid	134	4	4	0.0								40.3	56.0	3.7
	Streptomycin	134	≤ 32	> 64	30.6												69.4	6.7	23.9
	Trimethoprim-sulfamethoxazole	134	≤ 0.12	0.50	6.7				59.7	29.9	3.7				6.7
III	Chloramphenicol	134	8	> 32	23.9								3.7	30.6	39.6	2.2	0.7	23.1
	Sulfisoxazole	134	32	> 256	34.3											4.5	52.2	9.0			34.3
	Tetracycline	134	≤ 4	> 32	32.8									67.2			4.5	28.4
IV

Table B.9. Distribution of minimal inhibitory concentrations for antimicrobials in Escherichia coli isolates from beef cattle; Abattoir Surveillance, 2008.

Information on how to interpret the MIC tables is provided at the beginning of Appendix B.

Table B.9. - Text Equivalent

Antimicrobial		n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
			MIC 50	MIC 90		≤ 0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	> 256
I	Amoxicillin-clavulanic acid	176	4	4	0.0							7.4	33.5	52.8	6.3
	Ceftiofur	176	0.25	0.50	0.0				7.4	51.1	40.9	0.6
	Ceftriaxone	176	≤ 0.25	≤ 0.25	0.0					100.0
	Ciprofloxacin	176	≤ 0.015	≤ 0.015	0.0	97.7	2.3
II	Amikacin	176	2	2	0.0						1.1	26.7	62.5	8.0	1.7
	Ampicillin	176	2	4	1.1							19.9	54.0	23.3	1.7			1.1
	Cefoxitin	176	4	8	0.0							3.4	27.3	57.4	10.2	1.7
	Gentamicin	176	0.50	0.50	0.0					8.5	83.0	8.0	0.6
	Kanamycin	176	≤ 8	≤ 8	2.8										97.2				2.8
	Nalidixic acid	176	2	4	0.0						0.6	14.2	73.3	10.8		1.1
	Streptomycin	176	≤ 32	64	14.8												85.2	8.0	6.8
	Trimethoprim-sulfamethoxazole	176	≤ 0.12	0.25	0.0				73.9	23.9	2.3
III	Chloramphenicol	176	8	8	2.8								2.3	42.0	50.0	2.8		2.8
	Sulfisoxazole	176	≤ 16	> 256	15.3											80.7	2.8		1.1		15.3
	Tetracycline	176	≤ 4	> 32	37.5									52.8	9.7	7.4	4.0	26.1
IV

Table B.10. Distribution of minimal inhibitory concentrations for antimicrobials in Escherichia coli isolates from beef, by province/region; Retail Meat Surveillance, 2008.

Information on how to interpret the MIC tables is provided at the beginning of Appendix B.
The Maritimes region includes New Brunswick, Nova Scotia, and Prince Edward Island.

Table B.10. - Text Equivalent

Antimicrobial		Province/region	n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
				MIC 50	MIC 90		≤ 0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	> 256
I	Amoxicillin-clavulanic acid	British Columbia	88	4	8	2.3							9.1	30.7	45.5	11.4	1.1	1.1	1.1
		Saskatchewan	134	4	4	0.7							4.5	30.6	59.7	4.5			0.7
		Ontario	185	4	4	1.1							7.0	35.1	48.6	7.0	1.1	0.5	0.5
		Québec	126	4	4	0.8							9.5	31.7	54.8	3.2			0.8
		Maritimes	39	4	4	2.6							5.1	38.5	53.8			2.6
	Ceftiofur	British Columbia	88	0.25	0.50	2.3				10.2	43.2	44.3					2.3
		Saskatchewan	134	0.25	0.50	0.7				6.7	47.8	44.8				0.7
		Ontario	185	0.25	0.50	1.1				7.6	55.7	35.7					1.1
		Québec	126	0.25	0.50	0.8				11.1	46.8	40.5	0.8			0.8
		Maritimes	39	0.25	0.50	2.6				2.6	56.4	35.9	2.6			2.6
	Ceftriaxone	British Columbia	88	≤ 0.25	≤ 0.25	2.3					97.7						2.3
		Saskatchewan	134	≤ 0.25	≤ 0.25	0.7					99.3					0.7
		Ontario	185	≤ 0.25	≤ 0.25	1.1					98.4		0.5				1.1
		Québec	126	≤ 0.25	≤ 0.25	0.8					99.2						0.8
		Maritimes	39	≤ 0.25	≤ 0.25	2.6					97.4					2.6
	Ciprofloxacin	British Columbia	88	≤ 0.015	≤ 0.015	0.0	97.7	2.3
		Saskatchewan	134	≤ 0.015	≤ 0.015	0.0	100.0
		Ontario	185	≤ 0.015	≤ 0.015	0.0	99.5	0.5
		Québec	126	≤ 0.015	≤ 0.015	0.0	99.2	0.8
		Maritimes	39	≤ 0.015	≤ 0.015	0.0	100.0
II	Amikacin	British Columbia	88	2	2	0.0							31.8	62.5	5.7
		Saskatchewan	134	2	2	0.0							29.1	65.7	5.2
		Ontario	185	2	2	0.0						0.5	23.2	70.3	5.9
		Québec	126	2	4	0.0							29.4	57.1	11.1	2.4
		Maritimes	39	2	2	0.0						5.1	35.9	59.0
	Ampicillin	British Columbia	88	2	4	5.7							21.6	47.7	23.9		1.1		5.7
		Saskatchewan	134	2	4	0.7							14.9	57.5	26.9				0.7
		Ontario	185	2	4	5.9							18.4	55.7	19.5	0.5			5.9
		Québec	126	2	4	2.4							16.7	56.3	23.0	1.6			2.4
		Maritimes	39	2	4	2.6							12.8	51.3	33.3				2.6
	Cefoxitin	British Columbia	88	4	8	2.3						1.1	5.7	22.7	56.8	9.1	2.3		2.3
		Saskatchewan	134	4	8	0.7							3.7	26.9	59.0	9.7			0.7
		Ontario	185	4	4	1.6							2.7	31.4	56.8	7.6		0.5	1.1
		Québec	126	4	4	0.8							7.1	28.6	55.6	7.9			0.8
		Maritimes	39	4	4	2.6							2.6	28.2	61.5	5.1		2.6
	Gentamicin	British Columbia	88	0.50	1	0.0					14.8	71.6	13.6
		Saskatchewan	134	0.50	0.50	0.0					10.4	80.6	8.2	0.7
		Ontario	185	0.50	1	1.1					9.2	75.7	13.5	0.5				1.1
		Québec	126	0.50	1	0.0					9.5	69.8	19.8	0.8
		Maritimes	39	0.50	1	0.0					33.3	56.4	10.3
	Kanamycin	British Columbia	88	≤ 8	≤ 8	2.3										97.7				2.3
		Saskatchewan	134	≤ 8	≤ 8	0.7										99.3				0.7
		Ontario	185	≤ 8	≤ 8	1.6										98.4				1.6
		Québec	126	≤ 8	≤ 8	4.8										94.4	0.8			4.8
		Maritimes	39	≤ 8	≤ 8	2.6										97.4				2.6
	Nalidixic acid	British Columbia	88	2	4	0.0							10.2	72.7	17.0
		Saskatchewan	134	2	2	0.0							4.5	85.8	9.7
		Ontario	185	2	2	0.0						0.5	9.7	81.6	8.1
		Québec	126	2	2	0.0							13.5	77.8	8.7
		Maritimes	39	2	2	0.0							10.3	84.6	5.1
	Streptomycin	British Columbia	88	≤ 32	≤ 32	9.1												90.9	5.7	3.4
		Saskatchewan	134	≤ 32	≤ 32	5.2												94.8	1.5	3.7
		Ontario	185	≤ 32	64	11.4												88.6	5.9	5.4
		Québec	126	≤ 32	≤ 32	7.1												92.9	4.0	3.2
		Maritimes	39	≤ 32	≤ 32	5.1												94.9		5.1
	Trimethoprim-sulfamethoxazole	British Columbia	88	≤ 0.12	0.25	0.0				71.6	28.4
		Saskatchewan	134	≤ 0.12	0.25	0.7				71.6	24.6	3.0				0.7
		Ontario	185	≤ 0.12	0.25	3.2				65.9	27.6	3.2				3.2
		Québec	126	≤ 0.12	0.25	0.8				75.4	22.2	1.6				0.8
		Maritimes	39	≤ 0.12	0.25	2.6				66.7	28.2		2.6			2.6
III	Chloramphenicol	British Columbia	88	8	8	0.0								5.7	35.2	56.8	2.3
		Saskatchewan	134	4	8	0.7								3.0	48.5	46.3	1.5		0.7
		Ontario	185	8	8	3.2								4.3	44.3	47.0	1.1	0.5	2.7
		Québec	126	4	8	0.8								6.3	46.8	41.3	4.8		0.8
		Maritimes	39	4	8	0.0								2.6	53.8	43.6
	Sulfisoxazole	British Columbia	88	≤ 16	32	9.1											79.5	11.4				9.1
		Saskatchewan	134	≤ 16	32	7.5											86.6	6.0				7.5
		Ontario	185	≤ 16	> 256	13.0											81.6	4.9			0.5	13.0
		Québec	126	≤ 16	32	7.9											88.9	3.2				7.9
		Maritimes	39	≤ 16	32	2.6											87.2	7.7	2.6			2.6
	Tetracycline	British Columbia	88	≤ 4	> 32	22.7									70.5	6.8	2.3	3.4	17.0
		Saskatchewan	134	≤ 4	> 32	20.1									76.1	3.7	3.7		16.4
		Ontario	185	≤ 4	> 32	20.5									76.2	3.2	3.2	3.2	14.1
		Québec	126	≤ 4	> 32	16.7									80.2	3.2	1.6	2.4	12.7
		Maritimes	39	≤ 4	32	17.9									66.7	15.4		12.8	5.1
IV

Table B.11. Distribution of minimal inhibitory concentrations for antimicrobials in Campylobacter isolates from beef cattle, by Campylobacter species; Abattoir Surveillance, 2008.

Information on how to interpret the MIC tables is provided at the beginning of Appendix B.
Campylobacter spp. include unidentified species, some of which may be intrinsically resistant to nalidixic acid.

Table B.11. - Text Equivalent

Antimicrobial		Species	n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
				MIC 50	MIC 90		≤ 0.016	0.032	0.064	0.125	0.25	0.5	1	2	4	8	16	32	64	> 64
I	Ciprofloxacin	Campylobacter coli	30	0.125	0.25	3.3				53.3	43.3							3.3
	Ciprofloxacin	Campylobacter jejuni	93	0.125	0.25	2.2			34.4	50.5	12.9					1.1		1.1
	Ciprofloxacin	Campylobacter spp.	5	0.25	0.25	0.0				20.0	80.0
	Telithromycin	Campylobacter coli	30	2	4	0.0								76.7	23.3
	Telithromycin	Campylobacter jejuni	93	1	2	0.0					3.2	25.8	60.2	10.8
	Telithromycin	Campylobacter spp.	5	0.5	4	0.0					40.0	40.0			20.0
II	Azithromycin	Campylobacter coli	30	0.125	0.25	0.0				56.7	40.0	3.3
	Azithromycin	Campylobacter jejuni	93	0.064	0.064	0.0	3.2	38.7	55.9	2.2
	Azithromycin	Campylobacter spp.	5	0.064	0.5	0.0		20.0	40.0		20.0	20.0
	Clindamycin	Campylobacter coli	30	1	1	0.0						33.3	63.3		3.3
	Clindamycin	Campylobacter jejuni	93	0.125	0.25	0.0			10.8	50.5	31.2	7.5
	Clindamycin	Campylobacter spp.	5	0.25	0.5	0.0				20.0	60.0	20.0
	Erythromycin	Campylobacter coli	30	2	2	0.0							3.3	93.3	3.3
	Erythromycin	Campylobacter jejuni	93	0.5	0.5	0.0				3.2	34.4	62.4
	Erythromycin	Campylobacter spp.	5	0.5	1	0.0				20.0	20.0	40.0	20.0
	Gentamicin	Campylobacter coli	30	0.5	1	0.0						70.0	30.0
	Gentamicin	Campylobacter jejuni	93	1	1	0.0						46.2	52.7	1.1
	Gentamicin	Campylobacter spp.	5	0.25	0.25	0.0				40.0	60.0
	Nalidixic acid	Campylobacter coli	30	16	16	3.3										16.7	76.7	3.3		3.3
	Nalidixic acid	Campylobacter jejuni	93	≤ 4	8	2.2									68.8	29.0				2.2
	Nalidixic acid	Campylobacter spp.	5	64	> 64	60.0												40.0	20.0	40.0
III	Florfenicol	Campylobacter coli	30	2	2	0.0							20.0	80.0
	Florfenicol	Campylobacter jejuni	93	1	1	0.0						20.4	74.2	5.4
	Florfenicol	Campylobacter spp.	5	1	1	0.0					40.0		60.0
	Tetracycline	Campylobacter coli	30	> 64	> 64	86.7							13.3							86.7
	Tetracycline	Campylobacter jejuni	93	64	> 64	60.2				18.3	17.2	4.3						2.2	32.3	25.8
	Tetracycline	Campylobacter spp.	5	16	32	60.0					20.0					20.0	40.0	20.0
IV

Chickens

Table B.12. Distribution of minimal inhibitory concentrations for antimicrobials in Salmonella isolates from chickens; Abattoir Surveillance, 2008.

Information on how to interpret the MIC tables is provided at the beginning of Appendix B.

Table B.12. - Text Equivalent

Antimicrobial		n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
			MIC 50	MIC 90		≤ 0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	> 256
I	Amoxicillin-clavulanic acid	234	≤ 1	32	11.5							82.9	0.9		3.8	0.9	2.6	9.0
	Ceftiofur	234	1	> 8	11.5						37.6	49.6	1.3		0.4	11.1
	Ceftriaxone	234	≤ 0.25	8	11.5					87.6	0.9				1.7	8.1	1.7
	Ciprofloxacin	234	≤ 0.015	0.03	0.0	84.6	15.0	0.4
II	Amikacin	234	1	2	0.0						6.8	52.6	38.5	2.1
	Ampicillin	234	≤ 1	> 32	16.2							79.9	3.4	0.4				16.2
	Cefoxitin	234	2	32	10.7							22.2	50.9	14.1	0.9	1.3	6.4	4.3
	Gentamicin	234	0.50	0.50	0.4					46.6	48.7	3.8		0.4			0.4
	Kanamycin	234	≤ 8	≤ 8	0.4										99.6				0.4
	Nalidixic acid	234	4	4	0.0						0.4	1.3	38.5	56.4	3.4
	Streptomycin	234	≤ 32	> 64	39.7												60.3	20.9	18.8
	Trimethoprim-sulfamethoxazole	234	≤ 0.12	0.25	0.0				87.6	11.1	1.3
III	Chloramphenicol	234	4	8	0.4								5.1	56.0	38.0	0.4		0.4
	Sulfisoxazole	234	32	64	3.0											14.1	65.0	16.7	1.3		3.0
	Tetracycline	234	≤ 4	> 32	41.0									59.0		0.4	2.6	38.0
IV

Table B.13. Distribution of minimal inhibitory concentrations for antimicrobials in Salmonella isolates from chicken, by province/region; Retail Meat Surveillance, 2008.

Information on how to interpret the MIC tables is provided at the beginning of Appendix B.
The Maritimes region includes New Brunswick, Nova Scotia, and Prince Edward Island.

Table B.13. - Text Equivalent

Antimicrobial		Province/region	n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
				MIC 50	MIC 90		≤ 0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	> 256
I	Amoxicillin-clavulanic acid	British Columbia	47	≤ 1	> 32	21.3							68.1	4.3		4.3	2.1	4.3	17.0
		Saskatchewan	64	≤ 1	≤ 1	4.7							90.6			4.7		1.6	3.1
		Ontario	139	≤ 1	16	9.4							85.6	0.7		1.4	2.9	1.4	7.9
		Québec	120	≤ 1	> 32	15.0							78.3	0.8		2.5	3.3	3.3	11.7
		Maritimes	12	≤ 1	> 32	16.7							83.3						16.7
	Ceftiofur	British Columbia	47	1	> 8	23.4						19.1	55.3	2.1		2.1	21.3
		Saskatchewan	64	1	1	4.7						37.5	56.3	1.6			4.7
		Ontario	139	1	8	10.1					0.7	40.3	48.2	0.7		0.7	9.4
		Québec	120	1	> 8	15.0						38.3	45.8	0.8			15.0
		Maritimes	12	1	> 8	16.7						50.0	33.3				16.7
	Ceftriaxone	British Columbia	47	≤ 0.25	16	23.4					76.6					6.4	12.8	4.3
		Saskatchewan	64	≤ 0.25	≤ 0.25	4.7					95.3						3.1	1.6
		Ontario	139	≤ 0.25	8	10.1					89.9					1.4	6.5	1.4	0.7
		Québec	120	≤ 0.25	16	15.0					85.0					0.8	8.3	5.0	0.8
		Maritimes	12	≤ 0.25	16	16.7					83.3						16.7
	Ciprofloxacin	British Columbia	47	≤ 0.015	≤ 0.015	0.0	95.7	2.1	2.1
		Saskatchewan	64	≤ 0.015	0.03	0.0	85.9	14.1
		Ontario	139	≤ 0.015	0.03	0.0	87.1	12.9
		Québec	120	≤ 0.015	0.03	0.0	82.5	16.7	0.8
		Maritimes	12	≤ 0.015	≤ 0.015	0.0	100.0
II	Amikacin	British Columbia	47	1	4	0.0							61.7	27.7	10.6
		Saskatchewan	64	1	2	0.0						14.1	51.6	32.8	1.6
		Ontario	139	1	2	0.0						11.5	56.8	30.2	0.7	0.7
		Québec	120	1	2	0.0						10.0	58.3	30.0	1.7
		Maritimes	12	2	2	0.0							50.0	50.0
	Ampicillin	British Columbia	47	≤ 1	> 32	27.7							70.2		2.1				27.7
		Saskatchewan	64	≤ 1	4	9.4							84.4	4.7	1.6				9.4
		Ontario	139	≤ 1	> 32	13.7							80.6	5.8					13.7
		Québec	120	≤ 1	> 32	20.8							75.0	3.3	0.8				20.8
		Maritimes	12	≤ 1	> 32	16.7							83.3						16.7
	Cefoxitin	British Columbia	47	2	32	21.3							8.5	44.7	19.1	4.3	2.1	14.9	6.4
		Saskatchewan	64	2	8	4.7							20.3	62.5	6.3	6.3		3.1	1.6
		Ontario	139	2	16	8.6							18.0	59.7	9.4	2.2	2.2	3.6	5.0
		Québec	120	2	32	14.2							20.8	51.7	11.7	0.8	0.8	9.2	5.0
		Maritimes	12	2	32	16.7							50.0	33.3				8.3	8.3
	Gentamicin	British Columbia	47	≤ 0.25	1	0.0					61.7	27.7	6.4		2.1	2.1
		Saskatchewan	64	≤ 0.25	0.50	0.0					56.3	42.2	1.6
		Ontario	139	≤ 0.25	0.50	0.7					62.6	36.0		0.7				0.7
		Québec	120	≤ 0.25	0.50	1.7					66.7	30.0	1.7				0.8	0.8
		Maritimes	12	0.50	0.50	8.3					16.7	75.0						8.3
	Kanamycin	British Columbia	47	≤ 8	≤ 8	0.0										100.0
		Saskatchewan	64	≤ 8	≤ 8	3.1										96.9				3.1
		Ontario	139	≤ 8	≤ 8	0.0										99.3	0.7
		Québec	120	≤ 8	≤ 8	0.8										98.3	0.8			0.8
		Maritimes	12	≤ 8	≤ 8	0.0										91.7	8.3
	Nalidixic acid	British Columbia	47	4	4	0.0							2.1	27.7	66.0	4.3
		Saskatchewan	64	4	4	0.0								29.7	67.2	3.1
		Ontario	139	4	4	0.0							1.4	27.3	67.6	3.6
		Québec	120	4	4	0.0							0.8	36.7	56.7	5.8
		Maritimes	12	4	4	0.0								25.0	75.0
	Streptomycin	British Columbia	47	≤ 32	> 64	29.8												70.2	19.1	10.6
		Saskatchewan	64	≤ 32	> 64	35.9												64.1	14.1	21.9
		Ontario	139	≤ 32	> 64	32.4												67.6	16.5	15.8
		Québec	120	≤ 32	> 64	30.8												69.2	16.7	14.2
		Maritimes	12	≤ 32	64	16.7												83.3	16.7
	Trimethoprim-sulfamethoxazole	British Columbia	47	≤ 0.12	0.25	0.0				51.1	48.9
		Saskatchewan	64	≤ 0.12	0.25	0.0				73.4	26.6
		Ontario	139	≤ 0.12	0.25	0.7				75.5	23.7					0.7
		Québec	120	≤ 0.12	0.25	0.0				69.2	30.8
		Maritimes	12	≤ 0.12	≤ 0.12	0.0				100.0
III	Chloramphenicol	British Columbia	47	8	8	2.1								2.1	38.3	55.3	2.1		2.1
		Saskatchewan	64	8	8	1.6								3.1	39.1	54.7	1.6		1.6
		Ontario	139	4	8	0.7								6.5	48.2	43.9	0.7		0.7
		Québec	120	4	8	0.0								2.5	48.3	45.8	3.3
		Maritimes	12	8	8	0.0									50.0	50.0
	Sulfisoxazole	British Columbia	47	32	64	6.4											19.1	48.9	23.4	2.1		6.4
		Saskatchewan	64	32	64	4.7											6.3	70.3	18.8			4.7
		Ontario	139	32	64	2.2											20.1	64.7	12.2	0.7		2.2
		Québec	120	32	64	4.2											24.2	55.0	15.8	0.8		4.2
		Maritimes	12	32	64	8.3												83.3	8.3			8.3
	Tetracycline	British Columbia	47	≤ 4	> 32	29.8									70.2			4.3	25.5
		Saskatchewan	64	≤ 4	> 32	35.9									64.1			4.7	31.3
		Ontario	139	≤ 4	> 32	36.0									63.3	0.7		6.5	29.5
		Québec	120	≤ 4	> 32	35.0									64.2	0.8		0.8	34.2
		Maritimes	12	≤ 4	≤ 4	8.3									91.7				8.3
IV

Table B.14. Distribution of minimal inhibitory concentrations for antimicrobials in Salmonella isolates from chickens; Surveillance of Animal Clinical Isolates, 2008.

Information on how to interpret the MIC tables is provided at the beginning of Appendix B.

Table B.14. - Text Equivalent

Antimicrobial		n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
			MIC 50	MIC 90		≤ 0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	> 256
I	Amoxicillin-clavulanic acid	209	≤ 1	> 32	15.8							78.9			2.9	2.4	2.4	13.4
	Ceftiofur	209	1	> 8	16.3					0.5	17.7	64.6	0.5	0.5	0.5	15.8
	Ceftriaxone	209	≤ 0.25	16	16.3					83.3			0.5	0.5	0.5	11.5	2.9		1.0
	Ciprofloxacin	209	≤ 0.015	0.03	0.0	88.0	12.0
II	Amikacin	209	1	2	0.0						7.2	63.6	27.8	1.4
	Ampicillin	209	≤ 1	> 32	21.1							72.7	6.2					21.1
	Cefoxitin	209	2	32	15.3							9.1	67.0	7.7	0.5	0.5	9.6	5.7
	Gentamicin	209	≤ 0.25	0.50	2.4					58.9	36.4	1.9		0.5		0.5	1.9
	Kanamycin	209	≤ 8	≤ 8	1.4										98.1	0.5			1.4
	Nalidixic acid	209	4	4	0.0								27.3	72.2	0.5
	Streptomycin	209	≤ 32	64	16.7												83.3	9.1	7.7
	Trimethoprim-sulfamethoxazole	209	≤ 0.12	0.25	0.0				78.5	21.5
III	Chloramphenicol	209	8	8	1.9									34.0	62.7	1.4		1.9
	Sulfisoxazole	209	32	64	5.3											5.3	71.8	17.2	0.5		5.3
	Tetracycline	209	≤ 4	> 32	18.2									80.9	1.0		0.5	17.7
IV

Table B.15. Distribution of minimal inhibitory concentrations for antimicrobials in Escherichia coli isolates from chickens; Abattoir Surveillance, 2008.

Information on how to interpret the MIC tables is provided at the beginning of Appendix B.

Table B.15. - Text Equivalent

Antimicrobial		n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
			MIC 50	MIC 90		≤ 0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	> 256
I	Amoxicillin-clavulanic acid	170	4	32	26.5							1.8	27.6	31.8	10.6	1.8	17.6	8.8
	Ceftiofur	170	0.50	8	20.0				2.4	32.9	35.3	4.1	1.8	3.5	11.8	8.2
	Ceftriaxone	170	≤ 0.25	16	22.9					70.6	2.4	3.5	0.6	1.8	8.8	8.8	3.5
	Ciprofloxacin	170	≤ 0.015	≤ 0.015	0.0	94.1	2.4	0.6	2.4	0.6
II	Amikacin	170	2	4	0.0						1.8	23.5	61.2	11.2	2.4
	Ampicillin	170	4	> 32	36.5							14.1	32.9	15.3	0.6	0.6		36.5
	Cefoxitin	170	4	> 32	25.9								14.1	45.3	12.4	2.4	7.6	18.2
	Gentamicin	170	0.50	8	7.6					10.0	59.4	15.3	1.8	3.5	2.4	3.5	4.1
	Kanamycin	170	≤ 8	> 64	20.0										79.4	0.6		0.6	19.4
	Nalidixic acid	170	2	4	3.5						1.8	12.4	69.4	12.9			2.4	1.2
	Streptomycin	170	≤ 32	> 64	43.5												56.5	17.6	25.9
	Trimethoprim-sulfamethoxazole	170	≤ 0.12	> 4	11.8				51.8	26.5	7.6	1.2	1.2		11.8
III	Chloramphenicol	170	4	8	2.9								4.1	47.1	45.3	0.6		2.9
	Sulfisoxazole	170	≤ 16	> 256	40.0											54.7	4.7	0.6			40.0
	Tetracycline	170	32	> 32	50.6									48.8	0.6		4.1	46.5
IV

Table B.16. Distribution of minimal inhibitory concentrations for antimicrobials in Escherichia coli isolates from chicken, by province/region ; Retail Meat Surveillance, 2008.

Information on how to interpret the MIC tables is provided at the beginning of Appendix B.
The Maritimes region includes New Brunswick, Nova Scotia, and Prince Edward Island.

Table B.16. - Text Equivalent

Antimicrobial		Province/region	n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
				MIC 50	MIC 90		≤ 0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	> 256
I	Amoxicillin-clavulanic acid	British Columbia	70	32	> 32	52.9							1.4	12.9	24.3	7.1	1.4	40.0	12.9
		Saskatchewan	91	4	32	20.9							9.9	18.7	31.9	14.3	4.4	14.3	6.6
		Ontario	150	4	32	27.3							3.3	24.7	33.3	10.0	1.3	18.0	9.3
		Québec	131	4	32	22.1							6.1	27.5	32.8	9.9	1.5	15.3	6.9
		Maritimes	37	4	32	27.0							18.9	21.6	29.7	2.7		24.3	2.7
	Ceftiofur	British Columbia	70	4	> 8	48.6				1.4	17.1	22.9	4.3		5.7	34.3	14.3
		Saskatchewan	91	0.50	8	19.8				5.5	33.0	40.7			1.1	18.7	1.1
		Ontario	150	0.50	> 8	24.0				1.3	29.3	41.3			4.0	12.0	12.0
		Québec	131	0.50	8	18.3				3.8	33.6	37.4	3.1		3.8	10.7	7.6
		Maritimes	37	0.50	8	18.9					40.5	32.4		2.7	5.4	13.5	5.4
	Ceftriaxone	British Columbia	70	4	16	54.3					41.4	1.4	2.9		5.7	18.6	28.6	1.4
		Saskatchewan	91	≤ 0.25	8	20.9					79.1				1.1	13.2	6.6
		Ontario	150	≤ 0.25	16	28.0					71.3	0.7			3.3	8.0	15.3	1.3
		Québec	131	≤ 0.25	16	21.4					76.3	1.5		0.8	3.1	7.6	9.2	1.5
		Maritimes	37	≤ 0.25	8	27.0					73.0				8.1	10.8	8.1
	Ciprofloxacin	British Columbia	70	≤ 0.015	≤ 0.015	0.0	91.4	4.3			4.3
		Saskatchewan	91	≤ 0.015	≤ 0.015	0.0	92.3	1.1		4.4	2.2
		Ontario	150	≤ 0.015	≤ 0.015	0.0	95.3	0.7		0.7	3.3
		Québec	131	≤ 0.015	≤ 0.015	0.8	90.1	0.8		0.8	6.1	1.5				0.8
		Maritimes	37	≤ 0.015	≤ 0.015	0.0	100.0
II	Amikacin	British Columbia	70	2	4	0.0						2.9	12.9	74.3	10.0
		Saskatchewan	91	2	4	0.0							27.5	57.1	14.3	1.1
		Ontario	150	2	4	0.0						0.7	21.3	66.7	11.3
		Québec	131	2	4	0.0						0.8	18.3	68.7	10.7	1.5
		Maritimes	37	2	4	0.0							43.2	45.9	8.1	2.7
	Ampicillin	British Columbia	70	> 32	> 32	62.9							2.9	28.6	5.7				62.9
		Saskatchewan	91	4	> 32	40.7							17.6	28.6	12.1	1.1			40.7
		Ontario	150	4	> 32	39.3							8.0	38.0	14.7				39.3
		Québec	131	2	> 32	32.8							18.3	32.8	16.0				32.8
		Maritimes	37	2	> 32	29.7							27.0	32.4	10.8			2.7	27.0
	Cefoxitin	British Columbia	70	32	> 32	54.3								8.6	30.0	7.1		11.4	42.9
		Saskatchewan	91	4	> 32	20.9							3.3	13.2	47.3	13.2	2.2	4.4	16.5
		Ontario	150	4	> 32	28.0								13.3	47.3	10.7	0.7	4.7	23.3
		Québec	131	4	> 32	19.8								16.0	52.7	9.2	2.3	3.8	16.0
		Maritimes	37	4	> 32	24.3							5.4	18.9	35.1	10.8	5.4	5.4	18.9
	Gentamicin	British Columbia	70	0.50	1	5.7					7.1	71.4	15.7					5.7
		Saskatchewan	91	0.50	2	7.7					16.5	57.1	15.4	2.2		1.1	2.2	5.5
		Ontario	150	0.50	16	12.0					9.3	64.7	12.0			2.0	3.3	8.7
		Québec	131	0.50	> 16	20.6					5.3	61.8	11.5			0.8	9.2	11.5
		Maritimes	37	0.50	1	5.4					29.7	51.4	13.5				2.7	2.7
	Kanamycin	British Columbia	70	≤ 8	16	7.1										90.0	2.9			7.1
		Saskatchewan	91	≤ 8	> 64	12.1										84.6	3.3		1.1	11.0
		Ontario	150	≤ 8	16	9.3										88.7	2.0		0.7	8.7
		Québec	131	≤ 8	16	6.1										89.3	4.6			6.1
		Maritimes	37	≤ 8	16	8.1										89.2	2.7			8.1
	Nalidixic acid	British Columbia	70	2	4	4.3						1.4	14.3	67.1	11.4	1.4			4.3
		Saskatchewan	91	2	4	6.6						2.2	13.2	70.3	7.7			2.2	4.4
		Ontario	150	2	4	4.0							10.0	78.7	7.3				4.0
		Québec	131	2	4	8.4						1.5	15.3	68.7	5.3	0.8		1.5	6.9
		Maritimes	37	2	2	0.0						2.7	21.6	70.3	5.4
	Streptomycin	British Columbia	70	≤ 32	> 64	31.4												68.6	10.0	21.4
		Saskatchewan	91	≤ 32	> 64	28.6												71.4	14.3	14.3
		Ontario	150	≤ 32	> 64	33.3												66.7	10.7	22.7
		Québec	131	≤ 32	> 64	38.9												61.1	14.5	24.4
		Maritimes	37	≤ 32	> 64	29.7												70.3	8.1	21.6
	Trimethoprim-sulfamethoxazole	British Columbia	70	≤ 0.12	0.50	5.7				58.6	30.0	2.9	1.4	1.4		5.7
		Saskatchewan	91	≤ 0.12	0.25	3.3				67.0	23.1	5.5	1.1			3.3
		Ontario	150	≤ 0.12	0.50	6.7				53.3	31.3	6.7	1.3	0.7		6.7
		Québec	131	0.25	> 4	15.3				44.3	30.5	6.1	3.8		0.8	14.5
		Maritimes	37	0.25	> 4	16.2				35.1	45.9	2.7			2.7	13.5
III	Chloramphenicol	British Columbia	70	8	16	5.7								1.4	40.0	48.6	4.3		5.7
		Saskatchewan	91	4	8	3.3								1.1	56.0	37.4	2.2		3.3
		Ontario	150	4	8	4.7								4.7	50.0	40.0	0.7		4.7
		Québec	131	4	8	4.6								4.6	51.1	36.6	3.1		4.6
		Maritimes	37	4	8	8.1								2.7	64.9	24.3			8.1
	Sulfisoxazole	British Columbia	70	≤ 16	> 256	27.1											65.7	5.7		1.4		27.1
		Saskatchewan	91	≤ 16	> 256	19.8											72.5	5.5	2.2			19.8
		Ontario	150	≤ 16	> 256	30.7											61.3	8.0				30.7
		Québec	131	≤ 16	> 256	45.0											50.4	4.6				45.0
		Maritimes	37	≤ 16	> 256	29.7											59.5	8.1	2.7			29.7
	Tetracycline	British Columbia	70	≤ 4	> 32	45.7									54.3			1.4	44.3
		Saskatchewan	91	≤ 4	> 32	48.4									50.5	1.1		5.5	42.9
		Ontario	150	≤ 4	> 32	40.0									58.7	1.3	1.3	4.7	34.0
		Québec	131	≤ 4	> 32	45.0									54.2	0.8	1.5	5.3	38.2
		Maritimes	37	≤ 4	> 32	40.5									59.5		2.7	10.8	27.0
IV

Table B.17. Distribution of minimal inhibitory concentrations for antimicrobials in Campylobacter isolates from chicken, by Campylobacter species and province ; Retail Meat Surveillance, 2008.

Information on how to interpret the MIC tables is provided at the beginning of Appendix B.
Campylobacter spp. include unidentified species, some of which may be intrinsically resistant to nalidixic acid.

Table B.17. - Text Equivalent

Antimicrobial		Species	Province/region	n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
					MIC 50	MIC 90		≤ 0.016	0.032	0.064	0.125	0.25	0.5	1	2	4	8	16	32	64	> 64
I	Ciprofloxacin	Campylobacter coli	British Columbia	6	0.125	16	16.7			16.7	50.0	16.7						16.7
	Ciprofloxacin	Campylobacter coli	Saskatchewan	3	0.125	0.125	0.0				100.0
	Ciprofloxacin	Campylobacter coli	Ontario	16	0.125	0.25	6.3			12.5	43.8	37.5						6.3
	Ciprofloxacin	Campylobacter coli	Québec	5	0.125	0.25	0.0			40.0	20.0	40.0
	Ciprofloxacin	Campylobacter jejuni	British Columbia	44	0.125	0.25	6.8			43.2	31.8	18.2					4.5	2.3
	Ciprofloxacin	Campylobacter jejuni	Saskatchewan	37	0.125	8	10.8			43.2	35.1	10.8					10.8
	Ciprofloxacin	Campylobacter jejuni	Ontario	104	0.064	0.25	3.8			53.8	32.7	9.6					2.9		1.0
	Ciprofloxacin	Campylobacter jejuni	Québec	49	0.064	0.25	0.0			65.3	20.4	14.3
	Ciprofloxacin	Campylobacter spp.	British Columbia	0	0	0	0.0
	Ciprofloxacin	Campylobacter spp.	Saskatchewan	0	0	0	0.0
	Ciprofloxacin	Campylobacter spp.	Ontario	0	0	0	0.0
	Ciprofloxacin	Campylobacter spp.	Québec	0	0	0	0.0
	Telithromycin	Campylobacter coli	British Columbia	6	0.5	2	0.0					50.0	33.3		16.7
	Telithromycin	Campylobacter coli	Saskatchewan	3	0.25	1	0.0					66.7		33.3
	Telithromycin	Campylobacter coli	Ontario	16	4	16	12.5					18.8	6.3	6.3	12.5	43.8		12.5
	Telithromycin	Campylobacter coli	Québec	5	0.5	1	0.0						60.0	40.0
	Telithromycin	Campylobacter jejuni	British Columbia	44	0.5	1	0.0				2.3	13.6	45.5	34.1	4.5
	Telithromycin	Campylobacter jejuni	Saskatchewan	37	0.5	1	0.0				5.4	18.9	45.9	24.3	5.4
	Telithromycin	Campylobacter jejuni	Ontario	104	0.5	2	2.9					9.6	48.1	28.8	4.8	1.0	4.8	2.9
	Telithromycin	Campylobacter jejuni	Québec	49	0.5	8	2.0					8.2	57.1	18.4	4.1	2.0	8.2	2.0
	Telithromycin	Campylobacter spp.	British Columbia	0	0	0	0.0
	Telithromycin	Campylobacter spp.	Saskatchewan	0	0	0	0.0
	Telithromycin	Campylobacter spp.	Ontario	0	0	0	0.0
	Telithromycin	Campylobacter spp.	Québec	0	0	0	0.0
II	Azithromycin	Campylobacter coli	British Columbia	6	0.064	0.125	0.0		50.0	33.3	16.7
	Azithromycin	Campylobacter coli	Saskatchewan	3	0.064	0.064	0.0		33.3	66.7
	Azithromycin	Campylobacter coli	Ontario	16	0.125	> 64	18.8		12.5	31.3	12.5	25.0									18.8
	Azithromycin	Campylobacter coli	Québec	5	0.032	0.064	0.0		80.0	20.0
	Azithromycin	Campylobacter jejuni	British Columbia	44	0.064	0.064	0.0	6.8	34.1	50.0	6.8	2.3
	Azithromycin	Campylobacter jejuni	Saskatchewan	37	0.032	0.064	0.0	27.0	32.4	35.1	5.4
	Azithromycin	Campylobacter jejuni	Ontario	104	0.064	0.125	6.7	1.9	34.6	48.1	7.7		1.0								6.7
	Azithromycin	Campylobacter jejuni	Québec	49	0.064	> 64	12.2	4.1	30.6	51.0	2.0										12.2
	Azithromycin	Campylobacter spp.	British Columbia	0	0	0	0.0
	Azithromycin	Campylobacter spp.	Saskatchewan	0	0	0	0.0
	Azithromycin	Campylobacter spp.	Ontario	0	0	0	0.0
	Azithromycin	Campylobacter spp.	Québec	0	0	0	0.0
	Clindamycin	Campylobacter coli	British Columbia	6	0.25	0.5	0.0				33.3	50.0	16.7
	Clindamycin	Campylobacter coli	Saskatchewan	3	0.125	0.25	0.0				66.7	33.3
	Clindamycin	Campylobacter coli	Ontario	16	0.25	16	12.5				18.8	43.8	6.3	18.8				12.5
	Clindamycin	Campylobacter coli	Québec	5	0.064	0.25	0.0			60.0	20.0	20.0
	Clindamycin	Campylobacter jejuni	British Columbia	44	0.125	0.25	0.0			22.7	47.7	27.3			2.3
	Clindamycin	Campylobacter jejuni	Saskatchewan	37	0.125	0.25	0.0		5.4	32.4	43.2	13.5	5.4
	Clindamycin	Campylobacter jejuni	Ontario	104	0.125	0.5	2.9			10.6	59.6	17.3	5.8		1.0	2.9			2.9
	Clindamycin	Campylobacter jejuni	Québec	49	0.125	4	2.0			14.3	55.1	18.4			2.0	8.2	2.0
	Clindamycin	Campylobacter spp.	British Columbia	0	0	0	0.0
	Clindamycin	Campylobacter spp.	Saskatchewan	0	0	0	0.0
	Clindamycin	Campylobacter spp.	Ontario	0	0	0	0.0
	Clindamycin	Campylobacter spp.	Québec	0	0	0	0.0
	Erythromycin	Campylobacter coli	British Columbia	6	0.25	0.5	0.0					66.7	33.3
	Erythromycin	Campylobacter coli	Saskatchewan	3	0.25	0.5	0.0					66.7	33.3
	Erythromycin	Campylobacter coli	Ontario	16	2	> 64	18.8					12.5	18.8	12.5	31.3	6.3			6.3		12.5
	Erythromycin	Campylobacter coli	Québec	5	0.25	0.5	0.0				20.0	40.0	40.0
	Erythromycin	Campylobacter jejuni	British Columbia	44	0.25	1	0.0			4.5	9.1	45.5	29.5	9.1	2.3
	Erythromycin	Campylobacter jejuni	Saskatchewan	37	0.25	0.5	0.0			2.7	21.6	51.4	24.3
	Erythromycin	Campylobacter jejuni	Ontario	104	0.25	1	6.7				5.8	54.8	23.1	6.7	1.9	1.0					6.7
	Erythromycin	Campylobacter jejuni	Québec	49	0.5	> 64	12.2				10.2	36.7	38.8	2.0						2.0	10.2
	Erythromycin	Campylobacter spp.	British Columbia	0	0	0	0.0
	Erythromycin	Campylobacter spp.	Saskatchewan	0	0	0	0.0
	Erythromycin	Campylobacter spp.	Ontario	0	0	0	0.0
	Erythromycin	Campylobacter spp.	Québec	0	0	0	0.0
	Gentamicin	Campylobacter coli	British Columbia	6	0.5	1	0.0					33.3	33.3	33.3
	Gentamicin	Campylobacter coli	Saskatchewan	3	1	1	0.0							100.0
	Gentamicin	Campylobacter coli	Ontario	16	0.5	2	6.3						62.5	25.0	6.3					6.3
	Gentamicin	Campylobacter coli	Québec	5	0.5	0.5	0.0						100.0
	Gentamicin	Campylobacter jejuni	British Columbia	44	0.5	1	0.0					4.5	75.0	20.5
	Gentamicin	Campylobacter jejuni	Saskatchewan	37	0.5	1	0.0					2.7	67.6	29.7
	Gentamicin	Campylobacter jejuni	Ontario	104	0.5	1	0.0					1.9	67.3	30.8
	Gentamicin	Campylobacter jejuni	Québec	49	0.5	1	0.0					2.0	87.8	10.2
	Gentamicin	Campylobacter spp.	British Columbia	0	0	0	0.0
	Gentamicin	Campylobacter spp.	Saskatchewan	0	0	0	0.0
	Gentamicin	Campylobacter spp.	Ontario	0	0	0	0.0
	Gentamicin	Campylobacter spp.	Québec	0	0	0	0.0
	Nalidixic acid	Campylobacter coli	British Columbia	6	8	> 64	16.7									33.3	50.0				16.7
	Nalidixic acid	Campylobacter coli	Saskatchewan	3	≤ 4	≤ 4	0.0									100.0
	Nalidixic acid	Campylobacter coli	Ontario	16	8	16	6.3									43.8	43.8	6.3			6.3
	Nalidixic acid	Campylobacter coli	Québec	5	≤ 4	8	0.0									80.0	20.0
	Nalidixic acid	Campylobacter jejuni	British Columbia	44	≤ 4	8	6.8									70.5	20.5	2.3			6.8
	Nalidixic acid	Campylobacter jejuni	Saskatchewan	37	≤ 4	> 64	10.8									78.4	10.8				10.8
	Nalidixic acid	Campylobacter jejuni	Ontario	104	≤ 4	8	3.8									88.5	7.7				3.8
	Nalidixic acid	Campylobacter jejuni	Québec	49	≤ 4	8	0.0									81.6	18.4
	Nalidixic acid	Campylobacter spp.	British Columbia	0	0	0	0.0
	Nalidixic acid	Campylobacter spp.	Saskatchewan	0	0	0	0.0
	Nalidixic acid	Campylobacter spp.	Ontario	0	0	0	0.0
	Nalidixic acid	Campylobacter spp.	Québec	0	0	0	0.0
III	Florfenicol	Campylobacter coli	British Columbia	6	1	1	0.0							100.0
	Florfenicol	Campylobacter coli	Saskatchewan	3	1	1	0.0							100.0
	Florfenicol	Campylobacter coli	Ontario	16	1	2	0.0							68.8	31.3
	Florfenicol	Campylobacter coli	Québec	5	1	1	0.0						20.0	80.0
	Florfenicol	Campylobacter jejuni	British Columbia	44	1	2	0.0						4.5	84.1	11.4
	Florfenicol	Campylobacter jejuni	Saskatchewan	37	1	1	0.0						27.0	70.3	2.7
	Florfenicol	Campylobacter jejuni	Ontario	104	1	1	0.0						15.4	79.8	3.8	1.0
	Florfenicol	Campylobacter jejuni	Québec	49	1	1	0.0						12.2	83.7	4.1
	Florfenicol	Campylobacter spp.	British Columbia	0	0	0	0.0
	Florfenicol	Campylobacter spp.	Saskatchewan	0	0	0	0.0
	Florfenicol	Campylobacter spp.	Ontario	0	0	0	0.0
	Florfenicol	Campylobacter spp.	Québec	0	0	0	0.0
	Tetracycline	Campylobacter coli	British Columbia	6	8	> 64	33.3					33.3		16.7			16.7			16.7	16.7
	Tetracycline	Campylobacter coli	Saskatchewan	3	0.25	0.25	0.0				33.3	66.7
	Tetracycline	Campylobacter coli	Ontario	16	1	> 64	43.8				12.5	12.5	18.8	12.5					6.3		37.5
	Tetracycline	Campylobacter coli	Québec	5	0.5	64	20.0						80.0							20.0
	Tetracycline	Campylobacter jejuni	British Columbia	44	0.25	> 64	31.8			2.3	25.0	25.0	9.1		2.3	2.3	2.3		2.3	11.4	18.2
	Tetracycline	Campylobacter jejuni	Saskatchewan	37	8	> 64	48.6				16.2	32.4					2.7		24.3	5.4	18.9
	Tetracycline	Campylobacter jejuni	Ontario	104	32	> 64	50.0			1.9	23.1	18.3	6.7						4.8	18.3	26.9
	Tetracycline	Campylobacter jejuni	Québec	49	64	> 64	59.2				24.5	12.2	2.0	2.0					2.0	32.7	24.5
	Tetracycline	Campylobacter spp.	British Columbia	0	0	0	0.0
	Tetracycline	Campylobacter spp.	Saskatchewan	0	0	0	0.0
	Tetracycline	Campylobacter spp.	Ontario	0	0	0	0.0
	Tetracycline	Campylobacter spp.	Québec	0	0	0	0.0
IV

Table B.18. Distribution of minimal inhibitory concentrations for antimicrobials in Enterococcus isolates from chicken, by Enterococcus species and province; Retail Meat Surveillance, 2008.

Information on how to interpret the MIC tables is provided at the beginning of Appendix B.
^a Resistance to quinupristin-dalfopristin and lincomycin is not reported for E. faecalis because E. faecalis is intrinsically resistant to these antimicrobials.

Table B.18. - Text Equivalent

Antimicrobial		Species	Prov./ region	n	Percentile		% R	Distribution (%) of MICs (µg/mL)
					MIC 50	MIC 90		≤ 0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	512	1,024	2,048	> 2,048
I	Ciprofloxacin	Enterococcus faecalis	BC	70	1	2	0.0						4.3	74.3	21.4
			SA	85	1	2	1.2						1.2	80.0	17.6	1.2
			ON	148	1	2	1.4						2.7	75.0	20.9	0.7	0.7
			QC	133	1	2	0.0						1.5	80.5	18.0
		Enterococcus faecium	BC	3	1	2	0.0						33.3	33.3	33.3
			SA	1	2	2	0.0								100.0
			ON	3	4	4	66.7								33.3	66.7
			QC	5	1	> 4	20.0							60.0	20.0		20.0
		Enterococcus spp.	BC	4	1	1	0.0						25.0	75.0
			SA	5	0.25	2	0.0					60.0		20.0	20.0
			ON	3	0.5	2	0.0					33.3	33.3		33.3
			QC	4	0.5	1	0.0					50.0	25.0	25.0
	Daptomycin	Enterococcus faecalis	BC	70	1	1	0.0						25.7	71.4	2.9
			SA	85	1	1	0.0						24.7	74.1	1.2
			ON	148	1	1	0.0						36.5	62.2	1.4
			QC	133	1	1	0.0						27.8	70.7	1.5
		Enterococcus faecium	BC	3	2	2	0.0								100.0
			SA	1	4	4	0.0									100.0
			ON	3	2	4	0.0								66.7	33.3
			QC	5	2	4	0.0							20.0	60.0	20.0
		Enterococcus spp.	BC	4	2	2	0.0						25.0		75.0
			SA	5	2	4	0.0						20.0		60.0	20.0
			ON	3	≤ 0.5	≤ 0.5	0.0						100.0
			QC	4	1	2	0.0						50.0	25.0	25.0
	Linezolid	Enterococcus faecalis	BC	70	2	2	0.0							21.4	78.6
			SA	85	2	2	0.0							29.4	70.6
			ON	148	2	2	0.0							16.2	83.8
			QC	133	2	2	0.0							22.6	77.4
		Enterococcus faecium	BC	3	2	2	0.0							33.3	66.7
			SA	1	1	1	0.0							100.0
			ON	3	1	2	0.0							66.7	33.3
			QC	5	2	2	0.0							40.0	60.0
		Enterococcus spp.	BC	4	2	2	0.0							25.0	75.0
			SA	5	2	2	0.0							20.0	80.0
			ON	3	2	2	0.0						33.3		66.7
			QC	4	1	1	0.0							100.0
	Tigecycline	Enterococcus faecalis	BC	70	0.12	0.25	0.0			14.3	58.6	27.1
			SA	85	0.12	0.25	0.0			4.7	57.6	36.5	1.2
			ON	148	0.12	0.25	0.0			5.4	62.2	31.1	1.4
			QC	133	0.12	0.25	0.8			6.8	55.6	35.3	1.5	0.8
		Enterococcus faecium	BC	3	0.12	0.12	0.0			33.3	66.7
			SA	1	0.12	0.12	0.0				100.0
			ON	3	0.12	0.12	0.0			33.3	66.7
			QC	5	0.12	0.5	0.0			20.0	40.0	20.0	20.0
		Enterococcus spp.	BC	4	0.12	0.12	0.0			25.0	75.0
			SA	5	0.25	0.5	0.0			20.0	20.0	20.0	40.0
			ON	3	0.12	0.12	0.0				100.0
			QC	4	0.12	0.12	0.0			50.0	50.0
	Vancomycin	Enterococcus faecalis	BC	70	1	2	0.0							65.7	34.3
			SA	85	1	2	0.0							61.2	38.8
			ON	148	1	2	0.0						0.7	62.8	35.1	1.4
			QC	133	1	2	0.0						0.8	57.9	40.6	0.8
		Enterococcus faecium	BC	3	≤ 0.5	1	0.0						66.7	33.3
			SA	1	≤ 0.5	≤ 0.5	0.0						100.0
			ON	3	≤ 0.5	≤ 0.5	0.0						100.0
			QC	5	≤ 0.5	2	0.0						80.0		20.0
		Enterococcus spp.	BC	4	1	8	0.0						50.0	25.0			25.0
			SA	5	1	1	0.0						40.0	60.0
			ON	3	1	4	0.0						33.3	33.3		33.3
			QC	4	1	2	0.0						50.0	25.0	25.0
II	Erythromycin	Enterococcus faecalis	BC	70	> 8	> 8	54.3						18.6	12.9	14.3			54.3
			SA	85	> 8	> 8	69.4						20.0	5.9	4.7			69.4
			ON	148	4	> 8	49.3						31.1	12.2	6.8	0.7	2.0	47.3
			QC	133	> 8	> 8	54.9						29.3	12.0	3.8			54.9
		Enterococcus faecium	BC	3	2	> 8	33.3						33.3		33.3			33.3
			SA	1	> 8	> 8	100.0											100.0
			ON	3	> 8	> 8	100.0											100.0
			QC	5	> 8	> 8	80.0									20.0		80.0
		Enterococcus spp.	BC	4	1	4	0.0						50.0	25.0		25.0
			SA	5	2	> 8	20.0						40.0		20.0	20.0		20.0
			ON	3	≤ 0.5	> 8	33.3						66.7					33.3
			QC	4	> 8	> 8	100.0											100.0
	Gentamicin	Enterococcus faecalis	BC	70	≤ 128	≤ 128	4.3														95.7		2.9	1.4
			SA	85	≤ 128	≤ 128	3.5														96.5				3.5
			ON	148	≤ 128	≤ 128	4.7														95.3		0.7	0.7	3.4
			QC	133	≤ 128	512	10.5														87.2	2.3	6.8		3.8
		Enterococcus faecium	BC	3	≤ 128	≤ 128	0.0														100.0
			SA	1	≤ 128	≤ 128	0.0														100.0
			ON	3	≤ 128	≤ 128	0.0														100.0
			QC	5	≤ 128	≤ 128	0.0														100.0
		Enterococcus spp.	BC	4	≤ 128	≤ 128	0.0														100.0
			SA	5	≤ 128	≤ 128	0.0														100.0
			ON	3	≤ 128	≤ 128	0.0														100.0
			QC	4	≤ 128	≤ 128	0.0														100.0
	Kanamycin	Enterococcus faecalis	BC	70	≤ 128	> 1,024	20.0														78.6		1.4	2.9	17.1
			SA	85	≤ 128	> 1,024	24.7														74.1		1.2	2.4	22.4
			ON	148	≤ 128	> 1,024	15.5														83.8		0.7		15.5
			QC	133	≤ 128	> 1,024	21.8														77.4		0.8	0.8	21.1
		Enterococcus faecium	BC	3	256	> 1,024	33.3															66.7			33.3
			SA	1	256	256	0.0															100.0
			ON	3	256	256	0.0														33.3	66.7
			QC	5	≤ 128	256	0.0														60.0	40.0
		Enterococcus spp.	BC	4	≤ 128	≤ 128	0.0														100.0
			SA	5	≤ 128	256	0.0														80.0	20.0
			ON	3	≤ 128	≤ 128	0.0														100.0
			QC	4	≤ 128	≤ 128	0.0														100.0
	Lincomycina	Enterococcus faecium	BC	3	> 32	> 32	100.0											33.3		66.7
			SA	1	> 32	> 32	100.0													100.0
			ON	3	> 32	> 32	100.0													100.0
			QC	5	> 32	> 32	100.0										20.0			80.0
		Enterococcus spp.	BC	4	> 32	> 32	100.0												50.0	50.0
			SA	5	> 32	> 32	100.0											20.0		80.0
			ON	3	16	> 32	100.0											66.7		33.3
			QC	4	> 32	> 32	100.0													100.0
	Penicillin	Enterococcus faecalis	BC	70	4	4	0.0								28.6	71.4
			SA	85	4	4	0.0								40.0	60.0
			ON	148	4	4	0.0								33.8	66.2
			QC	133	4	4	0.0								24.1	75.9
		Enterococcus faecium	BC	3	2	> 16	33.3								66.7				33.3
			SA	1	16	16	100.0											100.0
			ON	3	16	16	66.7										33.3	66.7
			QC	5	8	16	40.0						20.0		20.0		20.0	40.0
		Enterococcus spp.	BC	4	4	> 16	25.0							25.0	25.0	25.0			25.0
			SA	5	2	16	20.0						20.0	20.0	20.0	20.0		20.0
			ON	3	≤ 0.5	1	0.0						66.7	33.3
			QC	4	1	2	0.0						50.0	25.0	25.0
	Quinupristin-dalfopristina	Enterococcus faecium	BC	3	2	8	33.3							33.3	33.3		33.3
			SA	1	16	16	100.0											100.0
			ON	3	16	16	100.0									33.3		66.7
			QC	5	16	32	80.0								20.0			40.0	40.0
		Enterococcus spp.	BC	4	8	8	50.0							25.0	25.0		50.0
			SA	5	8	8	80.0								20.0		80.0
			ON	3	2	2	0.0								100.0
			QC	4	16	16	100.0									25.0	25.0	50.0
Streptomycin	Enterococcus faecalis	BC	70	≤ 512	> 2,048	41.4																58.6	1.4	5.7	34.3
		SA	85	≤ 512	> 2,048	40.0																60.0		5.9	34.1
		ON	148	≤ 512	> 2,048	28.4																71.6	2.7	4.7	20.9
		QC	133	≤ 512	> 2,048	39.1																60.9	3.8	9.0	26.3
	Enterococcus faecium	BC	3	≤ 512	> 2,048	33.3																66.7			33.3
		SA	1	1,024	1,024	100.0																	100.0
		ON	3	≤ 512	≤ 512	0.0																100.0
		QC	5	≤ 512	≤ 512	0.0																100.0
	Enterococcus spp.	BC	4	≤ 512	≤ 512	0.0																100.0
		SA	5	≤ 512	2,048	20.0																80.0		20.0
		ON	3	≤ 512	≤ 512	0.0																100.0
		QC	4	≤ 512	1,024	25.0																75.0	25.0
Tylosin	Enterococcus faecalis	BC	70	> 32	> 32	52.9							10.0	35.7			1.4		52.9
		SA	85	> 32	> 32	69.4							5.9	24.7					69.4
		ON	148	> 32	> 32	50.0						0.7	5.4	43.2	0.7				50.0
		QC	133	> 32	> 32	54.1							6.0	38.3	0.8	0.8			54.1
	Enterococcus faecium	BC	3	4	> 32	33.3									66.7				33.3
		SA	1	> 32	> 32	100.0													100.0
		ON	3	> 32	> 32	100.0													100.0
		QC	5	> 32	> 32	80.0									20.0				80.0
	Enterococcus spp.	BC	4	1	2	0.0							75.0	25.0
		SA	5	2	> 32	20.0							20.0	60.0					20.0
		ON	3	2	> 32	33.3							33.3	33.3					33.3
		QC	4	> 32	> 32	100.0													100.0
III	Chloramphenicol	Enterococcus faecalis	BC	70	8	8	0.0									21.4	78.6
			SA	85	8	8	0.0									10.6	88.2	1.2
			ON	148	8	8	0.7									16.9	81.1	1.4	0.7
			QC	133	8	8	6.0									21.1	72.9		0.8	5.3
		Enterococcus faecium	BC	3	4	4	0.0									100.0
			SA	1	4	4	0.0									100.0
			ON	3	4	8	0.0									66.7	33.3
			QC	5	4	8	0.0									80.0	20.0
		Enterococcus spp.	BC	4	4	8	0.0								25.0	50.0	25.0
			SA	5	4	4	0.0									100.0
			ON	3	4	4	0.0									100.0
			QC	4	8	8	0.0									50.0	50.0
	Nitrofurantoin	Enterococcus faecalis	BC	70	8	16	0.0										55.7	41.4	2.9
			SA	85	8	16	0.0										55.3	42.4		2.4
			ON	148	8	16	0.0										56.1	35.8	4.1	4.1
			QC	133	8	16	0.0										60.9	32.3	3.8	3.0
		Enterococcus faecium	BC	3	64	> 64	33.3													66.7	33.3
			SA	1	> 64	> 64	100.0														100.0
			ON	3	> 64	> 64	66.7													33.3	66.7
			QC	5	64	> 64	20.0												20.0	60.0	20.0
		Enterococcus spp.	BC	4	> 64	> 64	50.0										25.0	25.0			50.0
			SA	5	> 64	> 64	60.0												20.0	20.0	60.0
			ON	3	16	32	0.0										33.3	33.3	33.3
			QC	4	> 64	> 64	75.0												25.0		75.0
	Tetracycline	Enterococcus faecalis	BC	70	> 32	> 32	75.7									22.9	1.4		8.6	67.1
			SA	85	> 32	> 32	85.9									14.1			7.1	78.8
			ON	148	> 32	> 32	89.2									10.8		0.7	8.8	79.7
			QC	133	> 32	> 32	86.5									13.5		0.8	6.8	78.9
		Enterococcus faecium	BC	3	32	> 32	66.7									33.3			33.3	33.3
			SA	1	> 32	> 32	100.0													100.0
			ON	3	> 32	> 32	100.0													100.0
			QC	5	> 32	> 32	80.0									20.0			20.0	60.0
		Enterococcus spp.	BC	4	32	> 32	75.0									25.0			50.0	25.0
			SA	5	> 32	> 32	80.0									20.0			20.0	60.0
			ON	3	≤ 4	≤ 4	0.0									100.0
			QC	4	> 32	> 32	100.0												50.0	50.0
IV	Flavomycin	Enterococcus faecalis	BC	70	≤ 1	≤ 1	0.0							100.0
			SA	85	≤ 1	≤ 1	0.0							100.0
			ON	148	≤ 1	≤ 1	0.7							96.6	2.0		0.7		0.7
			QC	133	≤ 1	≤ 1	0.8							95.5	3.0	0.8			0.8
		Enterococcus faecium	BC	3	16	> 16	33.3								33.3			33.3	33.3
			SA	1	2	2	0.0								100.0
			ON	3	4	8	0.0								33.3	33.3	33.3
			QC	5	16	> 16	40.0									40.0		20.0	40.0
		Enterococcus spp.	BC	4	> 16	> 16	50.0							25.0			25.0		50.0
			SA	5	4	> 16	40.0								20.0	40.0			40.0
			ON	3	8	> 16	33.3								33.3		33.3		33.3
			QC	4	> 16	> 16	50.0							50.0					50.0

Pigs

Table B.19. Distribution of minimal inhibitory concentrations for antimicrobials in Salmonella isolates from pigs; Farm Surveillance, 2008.

Information on how to interpret the MIC tables is provided at the beginning of Appendix B.

Table B.19. - Text Equivalent

Antimicrobial		n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
			MIC 50	MIC 90		≤ 0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	> 256
I	Amoxicillin-clavulanic acid	61	≤ 1	8	0.0							62.3	6.6		23.0	8.2
	Ceftiofur	61	1	1	0.0						27.9	68.9	3.3
	Ceftriaxone	61	≤ 0.25	≤ 0.25	0.0					100.0
	Ciprofloxacin	61	≤ 0.015	≤ 0.015	0.0	90.2	8.2	1.6
II	Amikacin	61	1	2	0.0							50.8	44.3	4.9
	Ampicillin	61	≤ 1	> 32	32.8							60.7	3.3	3.3			1.6	31.1
	Cefoxitin	61	2	4	0.0							4.9	49.2	42.6	3.3
	Gentamicin	61	0.50	1	1.6					37.7	47.5	11.5	1.6				1.6
	Kanamycin	61	≤ 8	> 64	21.3										78.7				21.3
	Nalidixic acid	61	4	4	0.0								36.1	60.7	3.3
	Streptomycin	61	≤ 32	> 64	36.1												63.9	9.8	26.2
	Trimethoprim-sulfamethoxazole	61	≤ 0.12	0.25	3.3				55.7	39.3	1.6				3.3
III	Chloramphenicol	61	8	> 32	24.6									23.0	50.8	1.6	1.6	23.0
	Sulfisoxazole	61	64	> 256	39.3											6.6	27.9	24.6	1.6		39.3
	Tetracycline	61	32	> 32	57.4									42.6			18.0	39.3
IV

Table B.20. Distribution of minimal inhibitory concentrations for antimicrobials in Salmonella isolates from pigs; Abattoir Surveillance, 2008.

Information on how to interpret the MIC tables is provided at the beginning of Appendix B.

Table B.20. - Text Equivalent

Antimicrobial		n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
			MIC 50	MIC 90		≤ 0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	> 256
I	Amoxicillin-clavulanic acid	151	≤ 1	16	1.3							66.9	5.3	2.0	13.2	11.3	1.3
	Ceftiofur	151	1	1	0.7					0.7	17.9	74.8	6.0			0.7
	Ceftriaxone	151	≤ 0.25	≤ 0.25	0.7					99.3						0.7
	Ciprofloxacin	151	≤ 0.015	0.03	0.0	76.2	21.2	2.6
II	Amikacin	151	1	2	0.0						2.0	49.0	45.7	3.3
	Ampicillin	151	≤ 1	> 32	27.8							57.0	12.6	2.0	0.7			27.8
	Cefoxitin	151	2	8	0.7							6.6	48.3	34.4	8.6	1.3		0.7
	Gentamicin	151	0.50	1	0.7					35.8	52.3	10.6	0.7				0.7
	Kanamycin	151	≤ 8	16	9.9										89.4	0.7			9.9
	Nalidixic acid	151	4	4	0.0								18.5	75.5	6.0
	Streptomycin	151	≤ 32	> 64	44.4												55.6	10.6	33.8
	Trimethoprim-sulfamethoxazole	151	≤ 0.12	0.50	6.6				52.3	30.5	7.9	1.3	1.3	0.7	6.0
III	Chloramphenicol	151	8	> 32	23.2									15.2	56.3	5.3		23.2
	Sulfisoxazole	151	64	> 256	46.4											7.9	28.5	17.2			46.4
	Tetracycline	151	32	> 32	57.6									42.4		1.3	17.9	38.4
IV

Table B.21. Distribution of minimal inhibitory concentrations for antimicrobials in Salmonella isolates from pork; Retail Meat Surveillance, 2003-2008.

Information on how to interpret the MIC tables is provided at the beginning of Appendix B.
The Maritimes region includes New Brunswick, Nova Scotia, and Prince Edward Island.

Table B.21. - Text Equivalent

Antimicrobial		Province/region	n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
				MIC 50	MIC 90		≤ 0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	> 256
I	Amoxicillin-clavulanic acid	British Columbia	4	≤ 1	≤ 1	0.0							100.0
		Saskatchewan	7	≤ 1	2	0.0							85.7	14.3
		Ontario	14	2	16	0.0							42.9	14.3	7.1	21.4	14.3
		Québec	9	≤ 1	> 32	11.1							55.6			22.2	11.1		11.1
		Maritimes	2	≤ 1	≤ 1	0.0							100.0
	Ceftiofur	British Columbia	4	1	1	0.0						50.0	50.0
		Saskatchewan	7	1	1	0.0						28.6	71.4
		Ontario	14	1	1	0.0						21.4	71.4	7.1
		Québec	9	1	> 8	11.1						22.2	66.7				11.1
		Maritimes	2	1	1	0.0						50.0	50.0
	Ceftriaxone	British Columbia	4	≤ 0.25	≤ 0.25	0.0					100.0
		Saskatchewan	7	≤ 0.25	≤ 0.25	0.0					100.0
		Ontario	14	≤ 0.25	≤ 0.25	0.0					100.0
		Québec	9	≤ 0.25	8	11.1					88.9					11.1
		Maritimes	2	≤ 0.25	≤ 0.25	0.0					100.0
	Ciprofloxacin	British Columbia	4	≤ 0.015	≤ 0.015	0.0	100.0
		Saskatchewan	7	≤ 0.015	0.03	0.0	71.4	28.6
		Ontario	14	≤ 0.015	0.03	0.0	85.7	7.1	7.1
		Québec	9	≤ 0.015	≤ 0.015	0.0	100.0
		Maritimes	2	≤ 0.015	≤ 0.015	0.0	100.0
II	Amikacin	British Columbia	4	1	1	0.0						25.0	75.0
		Saskatchewan	7	1	2	0.0						14.3	57.1	28.6
		Ontario	14	2	2	0.0							50.0	50.0
		Québec	9	1	4	0.0						11.1	66.7	11.1	11.1
		Maritimes	2	1	1	0.0							100.0
	Ampicillin	British Columbia	4	≤ 1	2	0.0							75.0	25.0
		Saskatchewan	7	≤ 1	2	0.0							71.4	28.6
		Ontario	14	16	> 32	42.9							50.0				7.1		42.9
		Québec	9	≤ 1	> 32	44.4							55.6						44.4
		Maritimes	2	2	2	0.0							50.0	50.0
	Cefoxitin	British Columbia	4	4	8	0.0								50.0	25.0	25.0
		Saskatchewan	7	2	4	0.0								57.1	42.9
		Ontario	14	2	4	0.0								57.1	35.7	7.1
		Québec	9	4	32	11.1							33.3	11.1	44.4			11.1
		Maritimes	2	4	4	0.0									100.0
	Gentamicin	British Columbia	4	≤ 0.25	≤ 0.25	0.0					100.0
		Saskatchewan	7	≤ 0.25	0.50	0.0					57.1	42.9
		Ontario	14	≤ 0.25	0.50	0.0					64.3	35.7
		Québec	9	≤ 0.25	0.50	0.0					55.6	44.4
		Maritimes	2	0.50	0.50	0.0					50.0	50.0
	Kanamycin	British Columbia	4	≤ 8	≤ 8	0.0										100.0
		Saskatchewan	7	≤ 8	≤ 8	0.0										100.0
		Ontario	14	≤ 8	> 64	14.3										85.7				14.3
		Québec	9	≤ 8	≤ 8	0.0										100.0
		Maritimes	2	≤ 8	≤ 8	0.0										100.0
	Nalidixic acid	British Columbia	4	2	4	0.0								75.0	25.0
		Saskatchewan	7	2	8	0.0								57.1	28.6	14.3
		Ontario	14	4	4	0.0							7.1	28.6	57.1		7.1
		Québec	9	4	4	0.0								33.3	66.7
		Maritimes	2	4	4	0.0								50.0	50.0
	Streptomycin	British Columbia	4	≤ 32	64	25.0												75.0	25.0
		Saskatchewan	7	> 64	> 64	85.7												14.3		85.7
		Ontario	14	≤ 32	64	35.7												64.3	28.6	7.1
		Québec	9	≤ 32	> 64	22.2												77.8	11.1	11.1
		Maritimes	2	> 64	> 64	50.0												50.0		50.0
	Trimethoprim-sulfamethoxazole	British Columbia	4	0.25	0.25	0.0				50.0	50.0
		Saskatchewan	7	0.25	0.25	0.0					100.0
		Ontario	14	0.25	> 4	14.3				42.9	35.7	7.1				14.3
		Québec	9	0.25	1	0.0				33.3	44.4	11.1	11.1
		Maritimes	2	≤ 0.12	≤ 0.12	0.0				100.0
III	Chloramphenicol	British Columbia	4	4	8	0.0									75.0	25.0
		Saskatchewan	7	> 32	> 32	57.1										42.9			57.1
		Ontario	14	8	> 32	28.6									7.1	57.1	7.1	7.1	21.4
		Québec	9	8	> 32	11.1									22.2	55.6	11.1		11.1
		Maritimes	2	8	8	0.0								50.0		50.0
	Sulfisoxazole	British Columbia	4	64	64	0.0											25.0	25.0	50.0
		Saskatchewan	7	> 256	> 256	85.7												14.3				85.7
		Ontario	14	128	> 256	42.9												35.7	14.3	7.1		42.9
		Québec	9	32	> 256	33.3												66.7				33.3
		Maritimes	2	32	32	0.0												100.0
	Tetracycline	British Columbia	4	> 32	> 32	75.0									25.0				75.0
		Saskatchewan	7	> 32	> 32	71.4									28.6				71.4
		Ontario	14	≤ 4	> 32	35.7									57.1	7.1	7.1	14.3	14.3
		Québec	9	≤ 4	> 32	44.4									55.6			11.1	33.3
		Maritimes	2	> 32	> 32	100.0													100.0
IV

Table B.22. Distribution of minimal inhibitory concentrations for antimicrobials in Salmonella isolates from pigs; Surveillance of Animal Clinical Isolates, 2008.

Information on how to interpret the MIC tables is provided at the beginning of Appendix B.

Table B.22. - Text Equivalent

Antimicrobial		n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
			MIC 50	MIC 90		≤ 0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	> 256
I	Amoxicillin-clavulanic acid	158	2	16	1.3							48.7	5.7	3.2	10.8	30.4	0.6	0.6
	Ceftiofur	158	1	1	1.3						7.6	87.3	3.8			1.3
	Ceftriaxone	158	≤ 0.25	≤ 0.25	1.3					98.7						0.6	0.6
	Ciprofloxacin	158	≤ 0.015	≤ 0.015	0.0	94.9	5.1
II	Amikacin	158	1	2	0.0						1.3	56.3	39.2	2.5	0.6
	Ampicillin	158	2	> 32	44.9							45.6	5.7	3.2		0.6	0.6	44.3
	Cefoxitin	158	2	4	1.9							3.2	53.8	36.7	3.8	0.6	0.6	1.3
	Gentamicin	158	0.50	1	1.9					35.4	51.3	10.8			0.6	0.6	1.3
	Kanamycin	158	≤ 8	> 64	17.7										81.6	0.6			17.7
	Nalidixic acid	158	4	4	0.0								36.1	60.8	3.2
	Streptomycin	158	64	> 64	55.7												44.3	23.4	32.3
	Trimethoprim-sulfamethoxazole	158	0.25	2	9.5				48.7	36.1	5.1		0.6		9.5
III	Chloramphenicol	158	8	> 32	34.8									8.9	51.9	4.4		34.8
	Sulfisoxazole	158	> 256	> 256	58.9											4.4	32.9	3.8			58.9
	Tetracycline	158	32	> 32	65.8									32.9	1.3	0.6	16.5	48.7
IV

Table B.23. Distribution of minimal inhibitory concentrations for antimicrobials in Escherichia coli isolates from pigs; Farm Surveillance, 2008.

Information on how to interpret the MIC tables is provided at the beginning of Appendix B.

Table B.23. - Text Equivalent

Antimicrobial		n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
			MIC 50	MIC 90		≤ 0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	> 256
I	Amoxicillin-clavulanic acid	1,425	4	8	1.2							3.2	27.9	39.4	26.9	1.3	1.0	0.2
	Ceftiofur	1,425	0.25	0.50	1.1				3.9	52.7	41.5	0.6		0.2	0.6	0.4
	Ceftriaxone	1,425	≤ 0.25	≤ 0.25	1.3					98.7	0.1			0.2	0.7	0.3	0.1
	Ciprofloxacin	1,425	≤ 0.015	≤ 0.015	0.0	97.9	1.7	0.2	0.1	0.1
II	Amikacin	1,425	2	4	0.0						1.3	30.2	56.6	10.6	1.2	0.1
	Ampicillin	1,425	2	> 32	34.0							9.3	40.8	14.5	1.1	0.3	0.3	33.8
	Cefoxitin	1,425	4	8	1.3						0.4	1.2	24.3	62.3	9.9	0.6	0.4	0.8
	Gentamicin	1,425	0.50	1	1.0					18.4	63.3	15.7	1.1	0.1	0.4	0.4	0.6
	Kanamycin	1,425	≤ 8	> 64	14.5										84.8	0.3	0.4	0.8	13.8
	Nalidixic acid	1,425	2	4	0.4						0.5	12.4	76.6	10.2			0.1	0.2
	Streptomycin	1,425	≤ 32	> 64	34.4												65.6	16.1	18.2
	Trimethoprim-sulfamethoxazole	1,425	0.25	> 4	10.0				45.3	33.8	9.4	1.3	0.1		10.0
III	Chloramphenicol	1,425	8	> 32	18.9								2.5	32.9	40.4	5.3	8.6	10.3
	Sulfisoxazole	1,425	32	> 256	47.9											48.1	3.6	0.3	0.2		47.9
	Tetracycline	1,425	> 32	> 32	79.4									20.4	0.2	0.9	4.5	74.0
IV

Table B.24. Distribution of minimal inhibitory concentrations for antimicrobials in Escherichia coli isolates from pigs; Abattoir Surveillance, 2008.

Information on how to interpret the MIC tables is provided at the beginning of Appendix B.

Table B.24. - Text Equivalent

Antimicrobial		n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
			MIC 50	MIC 90		≤ 0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	> 256
I	Amoxicillin-clavulanic acid	150	4	8	0.7							2.0	22.7	42.7	30.0	2.0	0.7
	Ceftiofur	150	0.25	0.50	0.7				4.0	48.7	46.0	0.7			0.7
	Ceftriaxone	150	≤ 0.25	≤ 0.25	0.7					98.7	0.7					0.7
	Ciprofloxacin	150	≤ 0.015	≤ 0.015	0.0	99.3				0.7
II	Amikacin	150	2	4	0.0						2.0	27.3	54.0	15.3	1.3
	Ampicillin	150	4	> 32	33.3							5.3	42.7	17.3	1.3			33.3
	Cefoxitin	150	4	8	0.0							1.3	23.3	63.3	10.7	1.3
	Gentamicin	150	0.50	1	2.0					12.0	67.3	17.3		1.3		2.0
	Kanamycin	150	≤ 8	> 64	18.7										81.3			0.7	18.0
	Nalidixic acid	150	2	4	0.7						1.3	8.7	79.3	10.0				0.7
	Streptomycin	150	≤ 32	> 64	35.3												64.7	18.0	17.3
	Trimethoprim-sulfamethoxazole	150	0.25	> 4	13.3				32.0	34.0	16.7	3.3	0.7		13.3
III	Chloramphenicol	150	8	32	24.7								1.3	28.0	42.0	4.0	16.7	8.0
	Sulfisoxazole	150	> 256	> 256	52.0											46.0	2.0				52.0
	Tetracycline	150	> 32	> 32	84.7									15.3		0.7	4.0	80.0
IV

Table B.25. Distribution of minimal inhibitory concentrations for antimicrobials in Escherichia coli isolates from pork; Retail Meat Surveillance, 2008.

Information on how to interpret the MIC tables is provided at the beginning of Appendix B.
The Maritimes region includes New Brunswick, Nova Scotia, and Prince Edward Island.

Table B.25. - Text Equivalent

Antimicrobial		Province/region	n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
				MIC 50	MIC 90		≤ 0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	> 256
I	Amoxicillin-clavulanic acid	British Columbia	44	4	8	6.8							4.5	15.9	52.3	20.5		2.3	4.5
		Saskatchewan	41	4	8	7.3							2.4	29.3	56.1	4.9		4.9	2.4
		Ontario	155	4	8	0.6							1.9	30.3	54.2	12.3	0.6	0.6
		Québec	60	4	8	3.3							3.3	36.7	40.0	16.7		1.7	1.7
		Maritimes	17	4	8	0.0							5.9	29.4	41.2	23.5
	Ceftiofur	British Columbia	44	0.25	0.50	6.8				6.8	47.7	36.4	2.3			4.5	2.3
		Saskatchewan	41	0.25	0.50	7.3				2.4	51.2	39.0				4.9	2.4
		Ontario	155	0.25	0.50	0.6				4.5	54.2	40.0	0.6			0.6
		Québec	60	0.25	0.50	3.3				8.3	53.3	33.3	1.7			1.7	1.7
		Maritimes	17	0.25	0.50	0.0				5.9	70.6	23.5
	Ceftriaxone	British Columbia	44	≤ 0.25	≤ 0.25	6.8					93.2					2.3	4.5
		Saskatchewan	41	≤ 0.25	≤ 0.25	7.3					92.7					2.4	2.4	2.4
		Ontario	155	≤ 0.25	≤ 0.25	0.6					99.4					0.6
		Québec	60	≤ 0.25	≤ 0.25	3.3					96.7					1.7		1.7
		Maritimes	17	≤ 0.25	≤ 0.25	0.0					100.0
	Ciprofloxacin	British Columbia	44	≤ 0.015	≤ 0.015	0.0	100.0
		Saskatchewan	41	≤ 0.015	≤ 0.015	0.0	97.6				2.4
		Ontario	155	≤ 0.015	≤ 0.015	0.0	99.4	0.6
		Québec	60	≤ 0.015	≤ 0.015	1.7	95.0			1.7	1.7					1.7
		Maritimes	17	≤ 0.015	≤ 0.015	0.0	100.0
II	Amikacin	British Columbia	44	2	4	0.0							20.5	56.8	22.7
		Saskatchewan	41	2	4	0.0							17.1	51.2	29.3	2.4
		Ontario	155	2	4	0.0							14.8	70.3	14.2	0.6
		Québec	60	2	4	0.0							21.7	56.7	21.7
		Maritimes	17	2	2	0.0							29.4	64.7	5.9
	Ampicillin	British Columbia	44	2	> 32	22.7							13.6	40.9	22.7				22.7
		Saskatchewan	41	2	4	9.8							12.2	51.2	26.8				9.8
		Ontario	155	2	> 32	16.8							11.6	43.9	26.5	1.3			16.8
		Québec	60	2	> 32	18.3							13.3	56.7	10.0	1.7			18.3
		Maritimes	17	2	> 32	17.6							11.8	47.1	23.5				17.6
	Cefoxitin	British Columbia	44	4	8	6.8								27.3	45.5	18.2	2.3		6.8
		Saskatchewan	41	4	8	7.3							2.4	17.1	61.0	12.2			7.3
		Ontario	155	4	8	0.6							0.6	23.2	60.0	12.9	2.6		0.6
		Québec	60	4	8	3.3							3.3	28.3	51.7	13.3		1.7	1.7
		Maritimes	17	4	4	0.0							5.9	29.4	58.8	5.9
	Gentamicin	British Columbia	44	0.50	1	4.5					9.1	65.9	20.5				2.3	2.3
		Saskatchewan	41	0.50	1	2.4					7.3	63.4	26.8					2.4
		Ontario	155	0.50	1	3.2					3.9	72.3	20.0			0.6	1.9	1.3
		Québec	60	0.50	1	1.7					6.7	70.0	18.3	3.3				1.7
		Maritimes	17	0.50	1	0.0					17.6	70.6	11.8
	Kanamycin	British Columbia	44	≤ 8	≤ 8	2.3										95.5	2.3			2.3
		Saskatchewan	41	≤ 8	≤ 8	2.4										95.1	2.4			2.4
		Ontario	155	≤ 8	≤ 8	3.2										96.1	0.6			3.2
		Québec	60	≤ 8	≤ 8	1.7										96.7	1.7			1.7
		Maritimes	17	≤ 8	> 64	11.8										88.2				11.8
	Nalidixic acid	British Columbia	44	2	2	0.0							18.2	72.7	9.1
		Saskatchewan	41	2	2	2.4							17.1	78.0	2.4				2.4
		Ontario	155	2	2	0.0							11.6	81.3	7.1
		Québec	60	2	4	5.0						1.7	16.7	70.0	6.7				5.0
		Maritimes	17	2	2	0.0							11.8	82.4	5.9
	Streptomycin	British Columbia	44	≤ 32	> 64	22.7												77.3	11.4	11.4
		Saskatchewan	41	≤ 32	64	14.6												85.4	9.8	4.9
		Ontario	155	≤ 32	64	14.2												85.8	5.8	8.4
		Québec	60	≤ 32	64	13.3												86.7	8.3	5.0
		Maritimes	17	≤ 32	64	11.8												88.2	11.8
	Trimethoprim-sulfamethoxazole	British Columbia	44	≤ 0.12	0.50	6.8				56.8	31.8	2.3	2.3			6.8
		Saskatchewan	41	≤ 0.12	0.25	0.0				56.1	39.0	2.4	2.4
		Ontario	155	≤ 0.12	0.50	7.1				56.8	27.7	6.5	1.9			7.1
		Québec	60	≤ 0.12	> 4	10.0				58.3	25.0	6.7				10.0
		Maritimes	17	0.25	> 4	11.8				35.3	47.1		5.9			11.8
III	Chloramphenicol	British Columbia	44	8	8	4.5								4.5	43.2	47.7		2.3	2.3
		Saskatchewan	41	8	8	0.0								4.9	41.5	48.8	4.9
		Ontario	155	4	8	9.0								3.9	50.3	36.1	0.6	3.9	5.2
		Québec	60	4	16	6.7								6.7	50.0	33.3	3.3	3.3	3.3
		Maritimes	17	8	8	5.9									41.2	52.9			5.9
	Sulfisoxazole	British Columbia	44	≤ 16	> 256	27.3											72.7					27.3
		Saskatchewan	41	≤ 16	> 256	12.2											80.5	7.3				12.2
		Ontario	155	≤ 16	> 256	20.6											72.9	6.5				20.6
		Québec	60	≤ 16	> 256	23.3											65.0	11.7				23.3
		Maritimes	17	≤ 16	> 256	17.6											76.5		5.9			17.6
	Tetracycline	British Columbia	44	≤ 4	> 32	45.5									54.5		4.5	4.5	36.4
		Saskatchewan	41	≤ 4	> 32	29.3									70.7		2.4		26.8
		Ontario	155	≤ 4	> 32	38.1									61.9		0.6	0.6	36.8
		Québec	60	≤ 4	> 32	35.0									65.0			3.3	31.7
		Maritimes	17	≤ 4	> 32	41.2									58.8			5.9	35.3
IV

Table B.26. Distribution of minimal inhibitory concentrations for antimicrobials in Enterococcus isolates from pigs, by Enterococcus species; Farm Surveillance, 2008.

Information on how to interpret the MIC tables is provided at the beginning of Appendix B.

Table B.26. - Text Equivalent

Antimicrobial		Species	n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
				MIC 50	MIC 90		≤ 0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	512	1,024	2,048	> 2,048
I	Ciprofloxacin	Enterococcus faecalis	918	1	2	0.2					0.1	2.8	70.2	26.7		0.2
	Ciprofloxacin	Enterococcus faecium	60	2	4	33.3						3.3	31.7	31.7	26.7	6.7
	Ciprofloxacin	Enterococcus spp.	288	0.5	1	1.0					14.2	60.4	17.4	6.9	0.7	0.3
	Daptomycin	Enterococcus faecalis	918	1	1	0.1						20.2	75.3	4.4	0.1		0.1
	Daptomycin	Enterococcus faecium	60	2	4	0.0						10.0	10.0	38.3	41.7
	Daptomycin	Enterococcus spp.	288	1	4	0.0						19.4	39.2	30.6	10.8
	Linezolid	Enterococcus faecalis	918	2	2	0.0						2.6	24.8	72.4	0.1
	Linezolid	Enterococcus faecium	60	2	2	0.0							6.7	93.3
	Linezolid	Enterococcus spp.	288	2	2	0.0						5.6	39.9	54.5
	Tigecycline	Enterococcus faecalis	918	0.25	0.25	1.6	0.3	1.2	3.2	37.6	50.1	6.0	1.6
	Tigecycline	Enterococcus faecium	60	0.12	0.5	1.7			1.7	50.0	35.0	11.7	1.7
	Tigecycline	Enterococcus spp.	288	0.12	0.25	2.1		2.1	13.2	52.8	25.0	4.9	2.1
	Vancomycin	Enterococcus faecalis	918	1	2	0.0						0.7	80.0	19.1	0.3
	Vancomycin	Enterococcus faecium	60	≤ 0.5	2	0.0						66.7	16.7	13.3	3.3
	Vancomycin	Enterococcus spp.	288	≤ 0.5	2	0.0						65.3	21.5	4.9	4.9	3.5
II	Erythromycin	Enterococcus faecalis	918	> 8	> 8	77.8						5.7	13.0	3.4	0.2	0.9	76.9
	Erythromycin	Enterococcus faecium	60	2	> 8	13.3						26.7	11.7	31.7	16.7	3.3	10.0
	Erythromycin	Enterococcus spp.	288	> 8	> 8	65.6						32.6	1.4	0.3		1.7	63.9
	Gentamicin	Enterococcus faecalis	918	≤ 128	256	8.1														89.8	2.2	4.4	2.1	1.6
	Gentamicin	Enterococcus faecium	60	≤ 128	≤ 128	0.0														100.0
	Gentamicin	Enterococcus spp.	288	≤ 128	≤ 128	1.7														96.9	1.4		1.0	0.7
	Kanamycin	Enterococcus faecalis	918	≤ 128	> 1,024	34.0														65.0	0.7	0.3	0.1	33.9
	Kanamycin	Enterococcus faecium	60	≤ 128	512	8.3														60.0	18.3	13.3		8.3
	Kanamycin	Enterococcus spp.	288	≤ 128	> 1,024	23.3														75.3	0.7	0.7	0.3	22.9
	Lincomycina	Enterococcus faecium	60	16	> 32	88.3							8.3		3.3	6.7	35.0	13.3	33.3
	Lincomycin	Enterococcus spp.	288	> 32	> 32	97.6							0.7	1.7			7.3	11.5	78.8
	Penicillin	Enterococcus faecalis	918	4	4	0.0						0.4	0.2	20.5	78.2	0.7
	Penicillin	Enterococcus faecium	60	2	8	3.3						8.3	15.0	30.0	36.7	6.7	3.3
	Penicillin	Enterococcus spp.	288	1	16	11.8						43.4	21.9	4.9	11.1	6.9	5.2	6.6
	Quinupristin- dalfopristina	Enterococcus faecium	60	2	4	11.7							30.0	58.3	10.0	1.7
	Quinupristin- dalfopristin	Enterococcus spp.	288	4	8	51.7							6.9	41.3	21.9	27.4	2.4
	Streptomycin	Enterococcus faecalis	918	≤ 512	> 2,048	47.2																52.8	3.9	13.8	29.4
	Streptomycin	Enterococcus faecium	60	≤ 512	≤ 512	8.3																91.7	6.7		1.7
	Streptomycin	Enterococcus spp.	288	≤ 512	> 2,048	28.8																71.2	7.6	8.7	12.5
	Tylosin	Enterococcus faecalis	918	> 32	> 32	78.0					0.1		8.4	13.1		0.4		0.1	77.9
	Tylosin	Enterococcus faecium	60	4	> 32	10.0							25.0	20.0	33.3	11.7			10.0
	Tylosin	Enterococcus spp.	288	> 32	> 32	66.3					0.3	0.3	6.6	22.6	3.5		0.3	0.3	66.0
III	Chloramphenicol	Enterococcus faecalis	918	8	8	7.4							0.1	0.4	10.3	79.5	2.2	2.5	4.9
	Chloramphenicol	Enterococcus faecium	60	4	8	0.0								1.7	70.0	26.7	1.7
	Chloramphenicol	Enterococcus spp.	288	4	8	5.9								5.2	56.9	31.6	0.3	3.5	2.4
	Nitrofurantoin	Enterococcus faecalis	918	8	16	0.9								0.1	1.2	74.8	21.2	0.4	1.3	0.9
	Nitrofurantoin	Enterococcus faecium	60	64	64	6.7											13.3	1.7	78.3	6.7
	Nitrofurantoin	Enterococcus spp.	288	32	> 64	18.8								0.3	2.4	17.7	6.9	35.8	18.1	18.8
	Tetracycline	Enterococcus faecalis	918	> 32	> 32	93.8									6.0	0.2	1.3	3.9	88.6
	Tetracycline	Enterococcus faecium	60	≤ 4	> 32	40.0									60.0			3.3	36.7
	Tetracycline	Enterococcus spp.	288	> 32	> 32	83.3									16.0	0.7	1.7	3.5	78.1
IV	Flavomycin	Enterococcus faecalis	918	≤ 1	≤ 1	0.4							93.4	6.2				0.4
	Flavomycin	Enterococcus faecium	60	> 16	> 16	93.3								3.3		1.7	1.7	93.3
	Flavomycin	Enterococcus spp.	288	16	> 16	48.3							17.4	9.4	9.0	8.7	7.3	48.3

^a Resistance to quinupristin-dalfopristin and lincomycin is not reported for E. faecalis because E. faecalis is intrinsically resistant to these antimicrobials.

Turkeys

Table B.27. Distribution of minimal inhibitory concentrations for antimicrobials in Salmonella isolates from turkeys; Surveillance of Animal Clinical Isolates, 2008.

Information on how to interpret the MIC tables is provided at the beginning of Appendix B.

Table B.27. - Text Equivalent

Antimicrobial		n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
			MIC 50	MIC 90		≤ 0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	> 256
I	Amoxicillin-clavulanic acid	32	> 32	> 32	56.3							43.8					3.1	53.1
	Ceftiofur	32	> 8	> 8	56.3						15.6	25.0	3.1			56.3
	Ceftriaxone	32	16	32	56.3					43.8						15.6	31.3	6.3	3.1
	Ciprofloxacin	32	≤ 0.015	≤ 0.015	0.0	96.9		3.1
II	Amikacin	32	2	2	0.0						3.1	46.9	40.6	9.4
	Ampicillin	32	> 32	> 32	56.3							40.6	3.1					56.3
	Cefoxitin	32	32	> 32	56.3						3.1	6.3	25.0	6.3	3.1		9.4	46.9
	Gentamicin	32	0.50	> 16	28.1					18.8	46.9	3.1	3.1				28.1
	Kanamycin	32	≤ 8	> 64	15.6										78.1	3.1	3.1		15.6
	Nalidixic acid	32	4	4	0.0								21.9	75.0	3.1
	Streptomycin	32	≤ 32	> 64	40.6												59.4	9.4	31.3
	Trimethoprim-sulfamethoxazole	32	≤ 0.12	0.25	3.1				68.8	28.1					3.1
III	Chloramphenicol	32	8	8	3.1									31.3	65.6			3.1
	Sulfisoxazole	32	32	> 256	31.3											21.9	37.5	9.4			31.3
	Tetracycline	32	≤ 4	> 32	43.8									56.3				43.8
IV

Horses

Table B.28. Distribution of minimal inhibitory concentrations for antimicrobials in Salmonella isolates from horses; Surveillance of Animal Clinical Isolates, 2008.

Information on how to interpret the MIC tables is provided at the beginning of Appendix B.

Table B.28. - Text Equivalent

Antimicrobial		n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
			MIC 50	MIC 90		≤ 0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	> 256
I	Amoxicillin-clavulanic acid	62	8	32	11.3							46.8	1.6		12.9	27.4	1.6	9.7
	Ceftiofur	62	1	> 8	11.3						32.3	56.5				11.3
	Ceftriaxone	62	≤ 0.25	16	11.3					88.7						9.7	1.6
	Ciprofloxacin	62	≤ 0.015	0.25	0.0	58.1	1.6			40.3
II	Amikacin	62	1	16	0.0						1.6	50.0	12.9	1.6	4.8	21.0	8.1
	Ampicillin	62	> 32	> 32	51.6							46.8	1.6					51.6
	Cefoxitin	62	2	32	11.3							35.5	41.9	11.3			8.1	3.2
	Gentamicin	62	0.50	> 16	41.9					33.9	22.6	1.6					41.9
	Kanamycin	62	≤ 8	> 64	41.9										58.1				41.9
	Nalidixic acid	62	4	16	0.0								14.5	45.2	27.4	12.9
	Streptomycin	62	≤ 32	≤ 32	4.8												95.2	3.2	1.6
	Trimethoprim-sulfamethoxazole	62	0.25	> 4	41.9				43.5	14.5					41.9
III	Chloramphenicol	62	8	> 32	16.1									27.4	56.5			16.1
	Sulfisoxazole	62	64	> 256	41.9											8.1	30.6	19.4			41.9
	Tetracycline	62	≤ 4	≤ 4	3.2									93.5	3.2			3.2
IV

Feed and Feed Ingredients

Table B.29. Distribution of minimal inhibitory concentrations for antimicrobials in Salmonella isolates from animal feed; Feed and Feed Ingredients, 2008.

Information on how to interpret the MIC tables is provided at the beginning of Appendix B.

Table B.29. - Text Equivalent

Antimicrobial		n	Percentiles		% R	Distribution (%) of MICs (µg/mL)
			MIC 50	MIC 90		≤ 0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16	32	64	128	256	> 256
I	Amoxicillin-clavulanic acid	57	≤ 1	≤ 1	1.8							94.7	1.8			1.8		1.8
	Ceftiofur	57	1	1	1.8						15.8	82.5				1.8
	Ceftriaxone	57	≤ 0.25	≤ 0.25	1.8					98.2								1.8
	Ciprofloxacin	57	≤ 0.015	≤ 0.015	0.0	94.7	5.3
II	Amikacin	57	1	2	0.0						3.5	49.1	45.6	1.8
	Ampicillin	57	≤ 1	≤ 1	3.5							94.7	1.8					3.5
	Cefoxitin	57	4	4	1.8							1.8	42.1	49.1	5.3			1.8
	Gentamicin	57	≤ 0.25	0.50	0.0					54.4	36.8	8.8
	Kanamycin	57	≤ 8	≤ 8	0.0										100.0
	Nalidixic acid	57	4	4	0.0								42.1	57.9
	Streptomycin	57	≤ 32	≤ 32	8.8												91.2	7.0	1.8
	Trimethoprim-sulfamethoxazole	57	≤ 0.12	0.25	1.8				75.4	22.8					1.8
III	Chloramphenicol	57	8	8	3.5								1.8	26.3	68.4			3.5
	Sulfisoxazole	57	32	64	5.3											24.6	42.1	28.1			5.3
	Tetracycline	57	≤ 4	≤ 4	5.3									94.7			1.8	3.5
IV